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Abstract
EFFECTS OF EMPHYSEMA AND CHRONIC HYPOXEMIA ON SKELETAL
MUSCLE OXYGEN SUPPLY AND DEMAND
By John D. Lowman Jr., Ph.D., P.T., C.C.S.
A dissertation submitted in partial fulfillment of the requirements for the Doctor of
Philosophy degree at the Medical College of Virginia Campus, Virginia Commonwealth
University.
Virginia Commonwealth University, 2004
Major Director: Dr. Roland N. Pittman, Professor, Department of Physiology

Skeletal muscle dysfunction in chronic obstructive pulmonary disease (COPD) is a
condition in which peripheral skeletal muscle undergoes myopathic changes which
impair muscle function, limit physical performance, and can lead to significant disability.
While the etiology of the dysfunction is unknown, this study was conducted to test the
hypothesis that chronic hypoxemia leads to alterations in oxygen transport and muscle
function. A primary objective was to validate elastase-induced emphysema in rats as an
animal model of skeletal muscle dysfunction in COPD.
Arterial blood gases were used to determine the severity of hypoxemia and sodium
dodecyl sulfate- polyacrylamide gel electrophoresis was used to determine the
proportions of myosin heavy chain isoforms I, IIa, IIx, and IIb. Measures of

xxviii

microvascular oxygenation and blood flow in the spinotrapezius muscle allowed for
determination of both convective and diffusive oxygen supply to the muscle, as well as
calculation of muscle oxygen consumption at rest and during electrically stimulated
three-minute muscle contractions. Muscle performance measures included peak force,
force-time integral, and fatigue index.
Due to a presumed rat respiratory virus, which likely resulted in the control group being
nearly as hypoxemic as the elastase-induced emphysema group, this study was not able to
definitively test the hypothesis that chronic hypoxemia leads to both a diminished supply
and demand of oxygen in skeletal muscle. Although many of the results of the present
study were not statistically significant, they exhibited consistent trends over time and are
likely of physiological significance. All measures of muscle performance were lower in
the emphysema group. In addition, spinotrapezius muscle oxygen consumption and
blood flow were lower in the emphysema group. The addition of supplemental oxygen
during isolated, small-muscle mass exercise did increase the force-time integral by ~18%
in both groups, suggesting that muscle work in these hypoxemic animals may be limited
by oxygen supply.
Thus, the data on muscle fiber type, oxygen consumption and muscle performance
suggest that elastase-induced emphysema in rats leads to a similar skeletal muscle
dysfunction that is observed in humans with COPD, and indicates that it is a valid animal
model of skeletal muscle dysfunction in COPD.

Introduction

COPD: definition and epidemiology
Chronic obstructive pulmonary disease (COPD), an umbrella term that primarily refers to

emphysema and chronic bronchitis (West 1997), is the fourth leading cause of death in
the U.S. (Anderson 2001), accounts for 1.7% of ambulatory care visits (NCHS 1999), and
costs an estimated $30.4 billion per year (ALA 2001). While the overall death rate in the
past 20 years has decreased 18%, COPD mortality has increased 42% (ALA 2001). The
death rate is even higher in mountainous high-altitude states where the partial pressure of
inspired oxygen (PIO2) is lower (Anderson 2001); however, oxygen therapy, which
increases PIO2, also increases exercise tolerance and quality of life, and decreases dyspnea
(shortness of breath) and mortality in chronically hypoxemic patients (NOTTG 1980;
Eaton, Garrett et al. 2002).

Hypoxia vs. hypoxemia: definition and causes
Hypoxia refers to low oxygen (O2) levels in general, and is often preceded by adjectives
that describe its location: alveolar hypoxia, tissue hypoxia, or cellular hypoxia. Cellular
hypoxia is functionally defined as the failure of convective or diffusive O2 transport to
meet the O2 demand such that the rate of adenosine triphosphate (ATP) synthesis is
1
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limited. Hypoxia can also be defined in terms of its etiology: 1) ischemic hypoxia, due
to blood-flow limitations, 2) anemic hypoxia, due to low hemoglobin concentrations, 3)
histotoxic or cytotoxic hypoxia, due to chemical poisoning of the cell, and 4) hypoxic
hypoxia, due to hypoxemia (Schumacker 1991).
Specifically, hypoxemia refers to a decreased arterial oxygen partial pressure (PaO2)
below the normal range (80-100 mmHg) (Pierson 2000). Obviously, hypoxemia can be a
cause of tissue or cellular hypoxia. Hypoxemia can be caused by: 1) hypoventilation, 2)
impaired diffusion across the alveolar blood-gas barrier, 3) ventilation-perfusion
mismatch, 4) intrapulmonary shunt, or 5) breathing a reduced PIO2 (West 1997).
Clinically, acute hypoxemia refers to a short-term (minutes to days), reversible cause of
hypoxemia (i.e., a patient recovering from pneumonia or anesthesia), while chronic
hypoxemia is a longer-term process (days to decades) and the cause is usually irreversible
(i.e., a patient with COPD or pulmonary fibrosis). Chronic hypoxemia in COPD is
primarily caused by ventilation-perfusion mismatch (ventilation of under perfused lung
tissue and/or perfusion of under ventilated lung tissue), but also by impaired diffusion
(decreased surface area available for gas exchange due to destruction of alveoli) and
hypoventilation (decreased minute ventilation due to an increased work of breathing)
(West 1998).
Research on “chronic hypoxia” is usually based on human or animal studies lasting less
than three months, what I shall refer to as “short-term chronic hypoxia.” Studies using

3

patients with COPD or permanent high-altitude residents will be referred to as “long-term
chronic hypoxia.” In most of these studies, the term hypoxia is used as opposed to

hypoxemia, because there were no measures to verify a low PaO2.

Skeletal muscle dysfunction in COPD
COPD results not only in impaired pulmonary function, but also well known
cardiovascular sequelae: pulmonary hypertension and right ventricular hypertrophy. In
addition, there are more poorly understood secondary effects on skeletal muscle, such as
impaired muscle strength and endurance. These impairments result in dyspnea (shortness
of breath), leg fatigue, and poor exercise tolerance (Zattara-Hartmann, Badier et al. 1995;
Serres, Gautier et al. 1998), and are the symptoms of the emerging syndrome “Skeletal
muscle dysfunction in COPD” (ATS/ERS 1999).
Skeletal muscle dysfunction in COPD is a debilitating disease that often leaves patients
anxious, homebound, and depressed because of their poor tolerance for physical activity,
including basic activities of daily living. A significant amount of research has focused on
characterizing this syndrome over the last 25 years, much of which will be reviewed
subsequently. The etiology of skeletal muscle dysfunction in COPD is unknown, but the
most likely causes include hypercapnia, inflammation, malnutrition, deconditioning
(decline in physical performance due to inactivity), and hypoxemia. The evidence seems
to favor deconditioning and/or hypoxemia (Richardson 1999), but uncoupling the two has
proved difficult in human studies.
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Oxygen transport in normal skeletal muscle
Oxygen transport to skeletal muscle by blood is regulated by adjusting O2 supply (cardiac
output, blood flow distribution, and the O2 capacity of the blood) to the O2 demand
(metabolic consumption) of the muscle (Weibel 1984). As far as O2 supply goes, I will
focus on blood flow distribution to and in skeletal muscle, and O2 capacity of the blood;
for the current discussion it is sufficient to say that cardiac output generally increases as
oxygen consumption increases.

Oxygen supply
Oxygen supply, or delivery, consists of both convective and diffusive flow of O2.

Convective delivery refers to the bulk flow of O2 bound to hemoglobin (Hb) in red blood
cells (RBCs) from the lung’s microvascular network (O2 source) to the muscle’s
microvascular network via the cardiovascular system, while diffusive delivery refers to
the flux of O2 out of the RBCs in the microcirculation to the mitochondria (O2 sink) in
the muscle fibers (Pittman 2000).
Convective O2 delivery
Based on Fick’s Principle, whole body convective O2 delivery ( Q OC2 ) is:
Equation 1
Q OC2 = Q ⋅ CaO 2
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where Q is total blood flow (cardiac output) and CaO2 is arterial O2 content (Pittman
2000). Tissue perfusion, and thus convective O2 delivery, is regulated by both total blood
flow and blood flow distribution. Altering blood flow distribution in response to changes
in local metabolism allows the fraction of cardiac output increase to metabolically active
tissues, while shunting blood away from less metabolically active tissue, and is altered by
modulating vascular resistance, which is under both neural and local regulation (Weibel
1984).
Diffusive O2 delivery
Diffusive O2 delivery ( Q OD2 ) is related to convective O2 delivery ( Q OC2 ) by:
Equation 2
Q OD2 = Q OC2 ( in ) − Q OC2 ( out )

where Q OC2 ( in ) and Q OC2 ( out ) are the convective flow of O2 into and out of the muscle tissue,
respectively (Pittman 2000). Equation 2 is related to Fick’s first law of diffusion that can
be expressed as:
Equation 3
Q OD2 = DO 2 ⋅ αO 2 ⋅ A ⋅ ∆PO 2 / ∆r

where DO 2 and αO 2 are the diffusion and solubility coefficients for oxygen, A is the
available surface area for diffusion, and ∆PO 2 / ∆r is the radial PO2 gradient (Pittman
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2000). As indicted by Equation 3, O2 will diffuse from one site to another provided the
driving force (∆PO2 = blood PO2 – intracellular PO2) is large enough and the diffusion
distance (∆r) is not too great. In fact, contrary to traditional views, Swain and Pittman
(1989) calculated that, in the hamster retractor muscle, about ⅔ of Q OD2 occurs in the
arterioles and about ⅓ in the capillaries.

DO2 and αO2 are relatively constant. However, if the number of perfused capillaries per
muscle fiber area increases, then A increases and diffusion distance decreases, causing O2
flux to increase. Diffusion distance can also be altered by changing the quantity and
location (subsarcolemmal vs. intermyofibrillar) of mitochondria, the O2 sink, in the
muscle (Weibel 1984). The other way to increase O2 flux is by increasing ∆PO2; this can
occur by: 1) shifts in the oxy-hemoglobin (Hb-O2) dissociation curve, 2) myoglobin
facilitated diffusion, and 3) increased consumption (see next section: Oxygen demand).
The Hb-O2 dissociation curve (Figure 1) can shift to the left or right by changes in 1)
muscle temperature, 2) carbon dioxide tension/pressure (PCO2), 3) hydrogen ion
concentration [H+], and 4) 2,3-diphosphoglycerate concentration [2,3-DPG] (Berne and
Levy 1998). Exercise, or muscular work, increases the first three of these factors,
shifting the curve to the right, which facilitates a higher blood PO2 for a given O2
saturation (SO2) of hemoglobin and enhances O2 flux by increasing ∆PO2.
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Figure 1. Hemoglobin-O2 dissociation curve (P50 = 36 mmHg).
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Myoglobin (Mb) facilitated diffusion increases O2 flux by several mechanisms. By
binding free O2 inside the muscle fiber, myoglobin lowers subsarcolemmal PO2, thus
increasing ∆PO2 and enhancing O2 flux. Myoglobin binding of O2 inside the fiber
decreases the diffusion distance for free O2. Lastly, due to the shape of the Mb-O2
dissociation curve (Figure 2) (Schenkman, Marble et al. 1997), myoglobin also buffers
mitochondrial PO2 by releasing bound O2 as intracellular PO2 decreases, which occurs
during muscle contraction as O2 is consumed, and intramuscular pressure compresses
blood vessels and impairs convective O2 supply (Honig, Gayeski et al. 1991).
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Oxygen demand
Within the mitochondria, the process of oxidative phosphorylation consumes O2 in
proportion to the need to produce ATP and replenish high energy phosphate stores within
the muscle. This O2 consumption by the mitochondria depletes cellular O2 stores, lowers
intracellular PO2, increases ∆PO2 and results in increased O2 demand. In skeletal muscle,
 ) can vary from 1.7 ml/min/kg at rest to over 70 ml/min/kg at
O2 consumption ( V
O2
 max (Weibel 1984; Aw and Jones 1990). This dramatic range of V
 requires
V
O2
O2

complex regulation of the O2 supply, but also provides a reserve capacity that is rarely
 reserve capacity as well as the ability of the muscle to
utilized. Due to this large V
O2

increase oxygen extraction, minor impairments in O2 supply do not pose a major threat to
the organism under normal functional conditions (i.e., the muscle tissue does not become
hypoxic). However, a major impairment in O2 supply (i.e., chronic hypoxemia) does
result in muscle tissue hypoxia, which has both cellular and systemic effects.

Effect of COPD and chronic hypoxemia on skeletal muscle
The effects of chronic hypoxemia on skeletal muscle are evident not only by cellular

changes within the muscle fibers themselves, but also include systemic effects, including
increased RBC production and microvascular changes. In the following literature
review, hypoxemia is the result of either 1) chronic lung disease, or 2) reduced PIO2. PIO2
can be reduced by 1) lowering the fraction of inspired O2 (FIO2) below that of room air
(0.21), and/or 2) decreasing the barometric pressure ((PB) hypobaric hypoxia); PB can be
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lowered in the lab using a hypobaric chamber or in the field by going to high altitudes
(normal PIO2 of room air at sea level is 150 mmHg).

Muscle fiber changes
Muscle fiber type
Specific muscle fiber types have been classified using several schemes. One of the first
was based on contractile speed (time-to-peak tension) and fatigability: slow-twitch,
fatigue resistant (S), fast-twitch, fatigue resistant (FR), fast-twitch, intermediate
fatigability (FI), and fast-twitch, fatigable (FF) (Burke, Levine et al. 1971). There are
two histochemical methods, one based on metabolic enzyme staining: slow-twitch
oxidative (SO), fast-twitch oxidative, glycolytic (FOG), and fast-twitch glycolytic (FG)
(Peter, Barnard et al. 1972), and the other based on pH lability of myofibrillar adenosine
triphosphatase (ATPase) staining: I, IIa, IIx, and IIb (Brooke and Kaiser 1970). More
recently, myosin heavy chain (MHC) immunoreactivity has been developed using
specific antibodies for different MHC isoforms: I, IIa, IIx, and IIb (Termin, Staron et al.
1989). Refer to Table 1 for a summary of how the classifications schemes compare.
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Table 1. Muscle-fiber type classification schemes.
Classification
Scheme
Twitch

Muscle-Fiber Type
S

FR

Metabolic
ATPase
MHC

SO
I
I

FOG
IIa
IIa

modified from ATS/ERS (1999)

FI

FF

IIx
IIx

FG
IIb
IIb
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The proportion of muscle fiber types from the vastus lateralis muscle of asymptomatic
elderly men is: 48% type I, 34% type IIa, and 17% type IIb. It varies slightly for
women: 54% type I, 41% type IIa, and 7% type IIb, but was only significantly different
for type IIb (due to rounding, these values total slightly more or less than 100%)
(Aniansson, Grimby et al. 1981). These numbers serve as reference values for the
ensuing discussion of fiber types in COPD, primarily a disease of the aged.
In a group of 18 patients with advanced COPD, with and without hypercapnia (PaCO2 >
40 mmHg), Jakobsson et al (1990) looked at the percentage of type I muscle fibers in the
vastus lateralis and found that patients with and without hypercapnia had abnormally low
percentages of type I fibers, 17 and 22% respectively, which were positively correlated to
PaO2, 58 and 78 mmHg, respectively, and were more than 50% lower than reference
values. A similar finding of decreased proportion of type I fibers, 29%, was found in
nine patients with a PaO2 of 63 mmHg (Hildebrand, Sylven et al. 1991). More recently,
Satta et al (1997) used the MHC classification in 22 borderline hypoxemic (mean PaO2 =
81 mmHg) patients with COPD (mean age 65). They reported a fiber transformation
from MHC I to MHC II2A to MHC2B, and in particular report a MHC2B proportion of
23% versus 7% for their control group (mean age 35). Using age matched controls (mean
age 65), Whittom et al (1998) also reported reduced type I and increased type IIb fibers
in patients with COPD. Even following lung transplantation (mean postoperative months
= 12, range 3 to 24), essentially curing hypoxemia, patients continue to have a lower
proportion of type I fibers, 25% vs. 56% for control (Wang, Williams et al. 1999).
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Contrary to the consistent evidence of fiber type transformation in patients with COPD,
the data are less conclusive regarding normal subjects exposed to hypobaric hypoxia. A
study of permanent, high-altitude residents (PIO2 ~90 mmHg), who did not regularly
exercise, found normal fiber type proportions: type I 50.8%, type IIa 30.3%, type IIb
15.4%, and 2.9% type IIab (Desplanches, Hoppeler et al. 1996). Green et al studied
mountaineers exposed to eight weeks of high altitude (5,000-8,484 m; PIO2 = 43-78
mmHg) and saw no change in fiber-type distribution (Green, Sutton et al. 1989).
However, in a later study he reported a 12% decrease in type I and a corresponding
increase in type IIa and IIb fibers following only three weeks at 4,300 m (PIO2 = 88
mmHg) (Green, Sutton et al. 1992).
Animal models of hypoxia are not conclusive either. Although Itoh et al (1990) found a
decrease in type I and increase in type II muscle fibers of rats exposed to 10 weeks at
4,000 m (PIO2 = 91 mmHg), Takahashi et al (1992) saw no fiber type transformation in
rats exposed to PIO2 of 71 mmHg for four weeks, a relatively short hypoxic period. van
Ekeren et al (1992), using a more pronounced hypoxia (PIO2 = 57 mmHg) in rats for
almost seven weeks, also reported no change in fiber type proportions.
Muscle mass/Cross sectional area
Muscle tissue mass and fiber cross-sectional area (FCSA) provide indices of muscle force
production or strength (Lieber 1992). Since a loss in lower extremity strength is a
hallmark of skeletal muscle dysfunction in COPD (Hamilton, Killian et al. 1995; Zattara-
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Hartmann, Badier et al. 1995), measurement of FCSA from vastus lateralis muscle
biopsies in chronically hypoxemic patients provides a reliable index of muscle fiber
atrophy.
Several studies found decreases in FCSA in patients with COPD (Hughes, Katz et al.
1983; Whittom, Jobin et al. 1998). Compared to age matched controls, Whittom reported
a 36% smaller FCSA for type I fibers, an 18% decrease for type IIa, and no difference in
type IIb.
Although some report no change in FCSA of human muscle in response to three weeks of
hypobaric hypoxia (Green, Sutton et al. 1992), muscle fiber atrophy appears to be a
consistent finding in most studies. Following up to two months at altitudes greater than
5,000 m (PIO2 < 78 mmHg), several investigators report a 20-25% decrease in both type I
and type II muscle FCSA (Green, Sutton et al. 1989; Hoppeler, Kleinert et al. 1990;
MacDougall, Green et al. 1991; Waynforth and Flecknell 1992).
Additional studies validate muscle atrophy as well as impaired hypertrophy in response to
training under hypoxic conditions. Rats exposed to PIO2 of 57 mmHg for 45 days had a
decrease in FCSA of both extensor and flexor lower extremity muscles (van Ekeren,
Sengers et al. 1992). Narici and Kayser (1995) compared the effects of strength training
for one month on hypertrophy in humans at sea level versus at 5,050 m (PIO2 ~77
mmHg); although they used elbow flexors and nuclear magnetic resonance imaging to
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measure cross sectional area, they found approximately 33% lower values for both
strength and muscle hypertrophy in the subjects trained at altitude.
Muscle fiber constituents
Several muscle fiber constituents are altered during chronic hypoxemia. Myoglobin
assists in the flux of O2 into and within the cell. Metabolic enzymes in the muscle fiber
serve to catabolize substrates (i.e., glucose and fatty acids) and produce ATP; the fate of
many intermediary products depends on the presence of O2. Many of these metabolic
processes take place within the mitochondria.
Myoglobin
Despite its role in the diffusive flux of O2 from the microvasculature to the mitochondria,
few studies have looked at myoglobin content in either COPD or chronic hypoxia. The
one study of patients with COPD and hypoxemia found a decreased myoglobin
concentration compared to healthy, age matched controls (Moller, Hellstrom et al. 1984).
However, the soleus muscle of guinea pigs exposed to 5,100 m (PIO2 = 78 mmHg) for 14
weeks had increased myoglobin content when matched for body mass to normoxic
animals (Sillau, Aquin et al. 1980).
Metabolic enzymes
Several groups have looked at metabolic enzyme activity in the vastus lateralis muscle of
humans exposed to hypobaric hypoxia (Green, Sutton et al. 1989; Howald, Pette et al.
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1990; Green, Sutton et al. 1992), with COPD (Jakobsson, Jorfeldt et al. 1995; Maltais,
Simard et al. 1996; Maltais, LeBlanc et al. 2000), or following lung transplantation
(Wang, Williams et al. 1999). Table 2 summarizes these results. In the hypobaric
hypoxia studies, the results are the percent change after exposure to ≥ 4,300 m for three
to six weeks. The results of the COPD and lung transplantation groups are percent
change compared to age matched controls. Of particular interest is the study by Maltais

et al in 2000, which compared 57 patients with COPD to sedentary controls.
The consistent finding is that processes taking place in the mitochondria (β oxidation,
citric acid cycle and oxidative phosphorylation) are either diminished or unchanged. In
all cases citrate synthase, the rate limiting step of the citric acid cycle, was reduced by an
average of ~32%. Evidence to substantiate an increase in glycolytic activity is less
conclusive. However, a decrease in the citrate synthase/phosphofructokinase ratio does
suggest a shift from aerobic to anaerobic production of ATP, presumably due to cellular
hypoxia, or insufficient O2 to support oxidative phosphorylation. It is unfortunate that
only two of these studies also looked at mitochondrial volume density; however, Howald

et al (1990) concluded that there was no enzymatic functional impairment, but the
diminished enzymatic activity was due to the loss of mitochondrial volume.
Mitochondria
Rats exposed to PIO2 57 mmHg for almost seven weeks exhibited a decrease in
subsarcolemmal mitochondrial volume density of both the soleus and extensor digitorum
longus muscles; however, the intermyofibrillar mitochondrial volume density of the
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soleus increased (van Ekeren, Sengers et al. 1992). When mountaineers were exposed to
≥ 5,300 m (PIO2 ≤ 75 mmHg) for up to two months, both their subsarcolemmal and
intermyofibrillar mitochondrial volume density had decreased 43 and 13%, respectively,
a 26% overall decrease (Hoppeler, Kleinert et al. 1990). A 30% lower mitochondrial
volume density has also been reported in young permanent high-altitude residents, 4,000
m (PIO2 = 91 mmHg), compared to age matched lowlanders (Hoppeler and Vogt 2001).
The only study of mitochondrial content in a patient population, expressed the yield of
mitochondrial protein as grams of protein per kilogram of muscle mass, reported a 43%
lower quantity in lung transplant patients when compared to healthy controls (Wang,
Williams et al. 1999).
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Table 2. Muscle enzyme activities.
Enzyme

Metabolic

Hypobaric

pathway

hypoxia

COPD

Lung
Tx

Green Howald Green Jakobsson Maltais Maltais Wang
(1989) (1990) (1992)

(1995)

↑ 16%

(1996) (2000) (1999)

Hexokinase

Glycolysis

↓ 53%

No ∆

No ∆

Phospho-

Glycolysis

No ∆

↑ 9%

↓ 14%

↑ 34%

No ∆

↑ 29%

β-Hydroxyacyl-

β oxidation of

No ∆

↓ 27%

No ∆

No ∆

↓ 44% ↓ 24% ↓ 43%

CoA-

fatty acids
↓ 29%

↓ 38% ↓ 24% ↓ 45%

fructokinase
(PFK)*

dehydrogenase
Citrate synthase

Citric acid cycle

↓ 37% ↓ 23%

Citric acid cycle

↓ 21%

(CS)*
Succinate

No ∆

No ∆

dehydrogenase
Malate

Citric acid cycle

↓ 19%

Cytochrome

Oxidative phos-

↓ 23%

oxidase

phorylation

dehydrogenase

CS/PFK ratio

↓ 38%

Mitochondrial

↓ 26%

content
* indicates rate limiting step

↓ 48%

↓ 58%
↓ 43%
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Microcirculatory changes
Due to the importance of the microcirculation to O2 delivery in skeletal muscle and the
potential for impaired O2 flux in chronic disease, the following is a review of the
anatomical (capillarity) and physiological (perfusion) changes in the microcirculation
related to chronic hypoxia.
Capillarity
Muscle capillarity is a measure of the quantity of local microcirculation that can be
measured by several different methods; each of these methods has advantages and
disadvantages, and may give varying results. Capillary density (CD, number of
capillaries per muscle FCSA), capillary-to-fiber ratio (C/F ratio), number of capillaries

around a fiber, and number of capillary contacts per FCSA are all commonly used
measures of capillarity, but do not take into account capillary tortuosity or sarcomere
length, both of which change with muscle contraction (Mathieu-Costello, Ellis et al.
1991). Mathieu-Costello (1991) argues that the best measure to assess a muscle’s
structural capacity for O2 flux is the capillary-to-fiber perimeter ratio, because it takes
into account the amount of area available for diffusion and does not vary with muscle
contraction; however, it has not become widely used and none of the subsequent articles
cited used this measure.
Only one study looked at capillarity in patients with and without COPD (Whittom, Jobin
et al. 1998). Although they saw a reduced number of capillary contacts per fiber, there
was no difference after correcting for the lower FCSA due to atrophy. Despite the fact
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that the 20 patients in the study had a moderately severe obstructive airway disease, they
were only borderline hypoxemic (PaO2 80 = mmHg), and thus may not have crossed the
threshold for changes in capillarity.
The topic of muscle capillarity has been studied by several investigators using either a
hypobaric chamber (Green, Sutton et al. 1989; MacDougall, Green et al. 1991), or field
studies of mountaineers in the Himalayas (Hoppeler, Kleinert et al. 1990). Subjects were
exposed to altitudes of 5,000 to 8,848 m (PIO2 ~78 – 43 mmHg) for a period of up to 60
days. Investigators consistently found an increased CD due to muscle fiber atrophy, and
an unchanged C/F ratio. However, permanent high-altitude residents have both a lower
CD and C/F ratio (Desplanches, Hoppeler et al. 1996).
Rats have also been used extensively in studies of hypoxia. Fisher (1992), looking at the

in vivo rat cremaster muscle after 50 days at ~6,000 m (PIO2 ~68 mmHg), saw not only an
increased capillary length density, but also increased number of perfused capillaries. In
several well-designed studies (Smith and Marshall 1999; Deveci, Marshall et al. 2001),
Marshall et al compared rats breathing a FIO2 of 0.12 (PIO2 ~86 mmHg) to controls
breathing room air; they saw a decreased PaO2 (41 vs. 86 mmHg), increased hematocrit
(50 vs. 43%), decreased body mass, and increased right ventricular mass (due to
pulmonary hypertension) following only 18 to 21 days of hypoxemia. Compared to
control animals, they also reported increased angiogenesis, evidenced by decreased

interbranch distance between 1°, 2°, and terminal arterioles, and an increased proportion
of 2° and terminal arterioles, from which O2 flux occurs more easily. It is unfortunate
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that these measures of capillarity, “length density,” and “interbranch distance,” cannot be
compared to other studies.
Perfusion
Few studies have looked at the in vivo physiology of blood flow in skeletal muscle during
chronic hypoxia. Cassin, in 1971, observed an increased perfusion of capillaries in rats
exposed to 6,150 m (PIO2 ~67 mmHg) for seven weeks that was not related to an increase
in capillarity, but rather opening of preexisting vessels (Cassin, Gilbert et al. 1971).
Nearly 20 years later, Fisher et al (1992), using the cremaster muscle, reported an
increase in both the anatomic and perfused capillary “length-density” in rats after 7
weeks at 6,000 m (PIO2 ~68 mmHg). They also saw an increased RBC flux and capillary
hematocrit, even when normalized to systemic hematocrit. In all, they found more
capillaries, increased perfusion of capillaries, and more RBCs in those capillaries; all
factors that serve to increase O2 flux into the muscle fiber.

Summary: Altered skeletal muscle O2 transport in chronic
hypoxemia
Due to the variance in method, intensity, frequency and duration of hypoxia in
experimental studies and use of different assessment techniques, conclusive evidence
does not exist regarding the precise effects of chronic hypoxemia on skeletal muscle
fibers or their associated microcirculation. Another major problem is clinical relevance:
most studies look at “short-term chronic hypoxia,” while patients with COPD may be
hypoxemic for decades, “long-term chronic hypoxia.” The following is a summary of the
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overall changes in O2 supply and demand in skeletal muscle in response to both COPD
and other modes of hypoxemia.

Supply changes
Both anatomical and physiological modifications occur locally in the microcirculation
and muscle fibers, as well as systemically, to increase the convective and diffusive flow of
O2 from the blood to the mitochondria and help prevent cellular hypoxia. Since the
systemic and pulmonary circulations are connected to the heart in series, pulmonary
hypertension and right heart failure, which can develop due to chronic hypoxemia, impair
systemic cardiac output and decrease convective O2 delivery ( Q OC2 ). In an effort to
compensate for the hypoxemia, the hormone erythropoietin is upregulated to increase
[Hb] and thus the quantity of O2 able to be convectively carried in the blood (CaO2). As
for systemic effects that increase diffusive O2 delivery, chronic hypoxemia increases
[2,3-DPG] levels which shifts the O2-Hb curve to the right, facilitating unloading; thus,
for a lower SO2, there is a higher blood PO2 and a larger driving force (∆PO2) to facilitate
O2 flux into the cell. In addition, PCO2 and [H+] increase with the severity of COPD
further shifting the Hb-O2 curve to the right.
It is debatable whether or not chronic hypoxemia promotes angiogenesis locally, or even
if there is a loss of capillarity. Following short-term chronic hypoxemia there appears to
be an increase in CD, while C/F ratio is maintained (Green, Sutton et al. 1989; Hoppeler,
Kleinert et al. 1990; MacDougall, Green et al. 1991). This argues against the idea of
capillary angiogenesis in humans exposed to hypoxia, because the increased CD is due to
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a decrease in muscle FCSA (Hoppeler and Vogt 2001). With or without angiogenesis, an
increased CD would mean a greater supply of O2 to the muscle per unit of contractile
mass due to increased capillary surface area per fiber area and decreased diffusion
distances associated with smaller fiber diameters. However, the Desplanches et al (1996)
study of permanent high-altitude residents reported that CD and C/F ratio were both
reduced in proportion to the loss of mitochondria and oxidative potential, suggesting that
O2 supply does decline over time.
Regardless of the number of capillaries per muscle fiber, these capillaries must be
perfused in order to participate in the diffusive flux of O2 into the muscle fiber. Although
few studies have looked at the in vivo perfusion of skeletal muscle following short-term
chronic hypoxia, those that have suggest an increase in the number of perfused capillaries
(Cassin, Gilbert et al. 1971; Fisher, Schrader et al. 1992). As mentioned above, this
would enhance O2 flux by increasing surface area and decreasing diffusion distance.
Also, the increased RBC supply rate and capillary hematocrit reported by Fisher et al
(1992) would potentially serve to increase convective O2 delivery, raising blood PO2,
thereby increasing the driving force for O2 diffusion into the muscle.
Another factor that would enhance O2 flux into the muscle fiber is an increase in muscle
myoglobin. While short-term hypoxia (14 days) increased [Mb] (Sillau, Aquin et al.
1980), hypoxemic patients with COPD had decreased [Mb] concentrations (Moller,
Hellstrom et al. 1984). Although traditionally regarded as consumers of O2, muscle
fibers can also improve the influx of O2 by the position of their mitochondria.
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Subsarcolemmal mitochondria decrease the diffusion distance for O2 when compared to
intermyofibrillar mitochondria. However, several studies report that there is a loss of
subsarcolemmal mitochondria (Hoppeler, Kleinert et al. 1990; van Ekeren, Sengers et al.
1992), which would also decrease the diffusion conductance of O2 by increasing
diffusion distance.

Demand changes
In the mitochondria, the enzyme cytochrome oxidase contains the final binding site for
O2 before it is reduced to H2O. Despite it’s importance, only one study (Howald, Pette et
al. 1990) has looked at cytochrome oxidase activity in short-term chronic hypoxia; they
found that it had decreased 23% in mountaineers following six weeks of exposure to a
PIO2 of ≤ 75 mmHg. Not surprisingly, this reduction was in close proportion to the 26%
decrease in mitochondrial volume density that they reported, and similar to the 30%
reduction seen in long-term chronic hypoxia (Hoppeler and Vogt 2001).
Muscle fiber type is relevant to the topic of O2 demand because different fiber types
derive their supply of ATP preferentially from different sources, type I from oxidative
phosphorylation and type IIb from glycolysis. Type I fibers not only require more O2
than type II for ATP synthesis, but since they contract more often (they are the first to be
activated and the last to fatigue), they consume more ATP and demand more O2. Thus, it
is not surprising that hypoxemic patients with COPD and permanent high-altitude
residents demonstrated a muscle fiber type transformation from I to II, as this would
decrease O2 demand.
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The consistent finding of muscle atrophy in nearly all studies of chronic hypoxia is also
significant in regard to O2 demand. Smaller cells contain fewer enzymes and contractile
proteins that must be synthesized and maintained at the expense of ATP and O2; thus,
fiber atrophy could be an adaptive response to diminished resources.

Conclusion
Taken as a whole, there seem to be significant differences in the effects of short-term
versus long-term chronic hypoxemia; however, the effects of both are attempts to
maintain homeostasis. Although the time sequence of the changes is not known, it
appears that short-term hypoxemia results in changes that increase O2 supply to skeletal
muscle. Despite these efforts to maintain normal tissue oxygenation, tissue PO2 remains
low and the muscle fibers undergo adaptive strategies in the first few months of
hypoxemia to decrease O2 demand: decreased fiber size, muscle fiber type
transformation, and decreased oxidative capacity (loss of mitochondria and aerobic
enzymes). Over the long-term, however, this decreased O2 demand leads to a decreased
O2 supply to the muscle, but the mechanism by which this occurs remains to be
discovered.
Therefore, the long-term changes seen in muscle fibers and their associated
microcirculation in response to chronic hypoxemia could be intended to decrease O2
conductance (supply and demand) in skeletal muscle in order to preserve blood PO2 for
more vital organs. This could explain why there is a persistent exercise limitation
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following lung transplantation, where the hypoxemia is cured, but its long-term effects
are not.

Animal model of COPD
The development of animal models of COPD, in particular emphysema, began in the mid1960’s with Eriksson’s discovery of α 1-antitrypsin deficiency (Laurell and Eriksson
1963; Eriksson 1965), and simultaneous with Gross’ finding of enzymatically produced
pulmonary emphysema (Gross, Babjak et al. 1964; Gross, Pfitzer et al. 1965). Since
1973, porcine pancreatic elastase has been the primary enzyme used to reliably reproduce
emphysema in animals (Kaplan, Kuhn et al. 1973; Lucey, Keane et al. 2002). Initially,
studies in hamsters focused on model and technique development of elastase-induced
emphysema (Kaplan, Kuhn et al. 1973), as well as documenting pulmonary histological,
stereological, and physiological changes that occur following elastase instillation (Kuhn
and Tavassoli 1976; Kuhn, Yu et al. 1976; Snider and Sherter 1977; Snider, Sherter et al.
1977). More recently, intratracheal elastase instillation has been validated as an
experimental model of emphysema in rats (Damon, Mauderly et al. 1982; Busch,
Buschbom et al. 1984; Busch, Lauhala et al. 1984; Sato, Kato et al. 1990; Finlay,
O'Donnell et al. 1996).
Animals treated with a single intratracheal instillation of porcine pancreatic elastase
exhibit the same characteristics as humans with emphysema (Snider, Lucey et al. 1986):
altered pulmonary function tests (increased residual volume, functional residual capacity,
and total lung capacity) (Snider and Sherter 1977; Snider, Sherter et al. 1977; Damon,
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Mauderly et al. 1982), impaired gas exchange (decreased diffusion capacity and arterial
blood oxygen levels) (O'Brien, Lucey et al. 1979; Lucey, O'Brien et al. 1980; Damon,
Mauderly et al. 1982; Sexton and Poole 1998), and cardiovascular sequelae (pulmonary
hypertension and right ventricular hypertrophy) (Icochea, Cooper et al. 1982; Sato, Kato
et al. 1994).
While the morphogenesis of emphysema begins within hours of the elastase instillation
(Kuhn, Yu et al. 1976; Busch, Lauhala et al. 1984), the structural changes in the lung are
relatively stable after six weeks (Snider and Sherter 1977). However, it is not known
how muscle morphology may change over time, or how oxygenation, blood flow, and
muscle function may be altered in animals with “stable” emphysema and chronic
hypoxemia.
To my knowledge, there are only two published investigations into the effects of chronic
emphysema on peripheral skeletal muscle. Mattson and Poole reported similar activity
levels between control and emphysematous hamsters (7 to 8 months old), but citrate
synthase levels in the vastus lateralis and gastrocnemius muscles were 7% and 13%
lower in the emphysematous hamsters (Mattson and Poole 1998). By contrast, in a
different study they reported no difference in hindlimb blood flow, using 15 µm-diameter
radiolabeled microspheres, but did find that blood flow to respiratory muscles in
emphysematous hamsters was higher during exercise than in controls (Sexton and Poole
1998). This group also found that microvascular PO2 in the diaphragm was ~35% lower
in emphysematous versus control hamsters.
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Spinotrapezius muscle
Gray originally described the spinotrapezius muscle preparation in 1973 as “an ideal
preparation for the microscopic study of a skeletal muscle vascular bed;” it is easily
accessible, thin enough for trans-illumination, and its neurovascular supply can remain
intact (Gray 1973). The spinotrapezius’ parallel muscle fibers originate from the spinous
processes of the 4th thoracic through the 3rd lumbar vertebrae, as well as a small segment
of the thoracolumbar fascia, and inserts onto the spine of the scapula. The muscle has
dual innervation from both cranial and peripheral nerves (spinal accessory (cranial nerve
XI), and 2nd and 3rd cervical nerves, respectively) (Gray 1973). Its main blood supply,
from the large spinotrapezius feeding artery (via subscapular branch of axillary artery),
enters near the scapula; a few other feeding arteries/arterioles enter the muscle either near
the caudal or cephalad border of the muscle (Schmid-Schonbein, Firestone et al. 1986)
(refer to Figure 3).
Since Gray’s original article, nearly 40 articles have been published using the
spinotrapezius muscle, either describing its anatomy (Engelson, Schmid-Schonbein et al.
1985; Engelson, Skalak et al. 1985; Engelson, Schmid-Schonbein et al. 1986; SchmidSchonbein, Firestone et al. 1986; Skalak and Schmid-Schonbein 1986; Saltzman, DeLano
et al. 1992), characterizing its contractile properties and fiber type (Taylor and Calvey
1977; Delp and Duan 1996), describing its normal microvascular physiology (Lash and
Bohlen 1987; Lash 1994; Suzuki, Poole et al. 1995; Musch and Poole 1996; Poole,
Musch et al. 1997; Kindig and Poole 1998; Lash 1998; Lash 1998; Kindig and Poole
1999; Richmond, Shonat et al. 1999; Bailey, Kindig et al. 2000; Behnke, Kindig et al.
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2001; Bishop, Nance et al. 2001; Kindig and Poole 2001; McDonough, Behnke et al.
2001; Behnke, Kindig et al. 2002; Bishop, Popel et al. 2002; Kindig, Richardson et al.
2002; Smith, Golub et al. 2002; Kano, Padilla et al. 2004) as well as functional and
microcirculatory changes associated with hypertension (Schmid-Schonbein, Firestone et
al. 1986; Lash and Bohlen 1995; Smith, Barbee et al. 2004; Smith, Barbee et al. 2004),
skeletal muscle ischemia (Suzuki, Poole et al. 1995), diabetes (Kindig, Sexton et al.
1998), chronic heart failure (Kindig, Musch et al. 1999; Richardson, Kindig et al. 2003;
Behnke, Delp et al. 2004), and aging (Russell, Kindig et al. 2003). The fact that surgical
exteriorization of the spinotrapezius does not alter microvascular PO2 and blood flow
when compared to the intact state (Bailey, Kindig et al. 2000) makes it an ideal tissue to
measure oxygen transport and consumption. Surprisingly, no one has used the
spinotrapezius muscle, or any other peripheral skeletal muscle, to investigate
microvascular oxygen transport or muscle contractile changes related to chronic
hypoxemia or COPD.
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Figure 3. Microvascular network of rat spinotrapezius muscle (Engelson, Skalak et
al. 1985).
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Purpose of present study
The overall purpose of this series of investigations was to test the hypothesis that the
principle of symmorphosis, regulated morphology “commensurate to functional needs”
(Weibel 1984; 2000), is operative under conditions of chronic hypoxia. If it is, then one
might expect that 1) chronic systemic hypoxemia leads to diminished oxygen demand
from the muscle due to slow-to-fast fiber type transformations and reduced oxidative
enzyme capacity, and 2) that this chronic reduction in tissue oxygen demand would
remove the stimulus for angiogenesis (i.e., vascular endothelial growth factor) and lead to
vascular rarefaction, further diminishing oxygen supply, as has been seen in other chronic
disease models (hypertension and heart failure) (Hansen-Smith, Greene et al. 1990; Nusz,
White et al. 2003). This proposed negative-feedback loop is illustrated in Figure 4.
There is no animal model of “skeletal muscle dysfunction in COPD,” but there is 1) an
excellent animal model of emphysema, and 2) an ideal skeletal muscle for studying the
microcirculation. Thus, the objectives of my study, in relation to the above hypothesis,
were to:
1. validate elastase-induced emphysema in rats as an animal model of skeletal
muscle dysfunction in COPD,
2. determine if there is a relationship during aging between severity of hypoxemia
and transformations in muscle fiber type,
3. investigate differences in oxygen transport and skeletal muscle function in the
spinotrapezius muscle of animals with and without COPD, and
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4. determine if short-term supplemental oxygen improves oxygen supply and muscle
performance of the spinotrapezius.
The independent measures included both local skeletal muscle O2 supply and demand
parameters, and muscle performance, as well as systemic measures of O2 supply and
evaluation of respiratory function.
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Figure 4. Proposed negative-feedback loop. As tissue O2 delivery becomes impaired,
so does muscle fiber O2 supply, and consequently O2 demand; likewise, as fiber O2
demand decreases during chronic hypoxia, this may lead to a decrease in O2 supply.

Materials, Methods, and Data Analysis

Based on the objectives of this study, there were two phases of this project:
I. validation of elastase-induced emphysema as an animal model of skeletal muscle
dysfunction in COPD (i.e., transformation of muscle fiber type with aging and
hypoxemia) and
II. investigation of oxygen consumption and skeletal muscle performance differences
in animals with and without COPD, and the effects of supplemental oxygen on
these parameters.
Each phase was preceded by the initial intervention: endotracheal instillation of either
elastase or saline. Many of the materials and methods were used in both phases of the
study; others were unique to one phase or the other. For convenience of reference, the
various experimental methods and techniques are described first, followed by the details
of each protocol. Further details of some aspects are found in the appendices. This study
was approved in advance by Virginia Commonwealth University’s Institutional Animal
Care and Use Committee (protocol # 0206-3081), and all animals were treated in
accordance with the Institute for Laboratory Animal Research’s Guide for the Care and

Use of Laboratory Animals (1996).
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Experimental Animals
Seventy-six Sprague-Dawley rats (Harlan, Indianapolis, IN) with a mean initial body
mass of 215.5 g (SD 14.5, range 176 – 248) were used in these experiments. Since the
spinotrapezius muscle of male rats is thicker and contains more connective tissue, giving
poorer image quality for intravital microscopy, female rats, which have a lower maximal
body mass (Figure 5), were used. Animals were housed in individual cages and
maintained on a 12:12 hr light-dark cycle in a climate-controlled room (temperature 6875° F, humidity 40-60%), with access to rodent chow and water ad libitum. Animals
were delivered to the institutional animal care facility at 8.3 (SD 0.6) weeks of age, and
were given two weeks for acclimatization. At a mean age of 10.6 (SD 0.7) weeks of age
(range 9.6 – 12.0), the initial intervention (intratracheal instillation, described in “Initial
intervention: Elastase/vehicle instillation,” page 41) was performed. The terminal
experiments were completed between 4 and 65 weeks after the initial intervention.
Following a purported outbreak of Rat respiratory virus, the 16 animals used in phase II
were housed in filter-top cages.
The influence of hypothermia, dehydration, infection, and pain were all addressed. To
prevent hypothermia, all animals were kept at ~37° C, verified by rectal thermometer
(Model 2018, Lumiscope, East Brunswick, NJ), using a homeothermic blanket system
(Harvard Apparatus, Holliston, MA) and/or a thermostatic animal platform (Appendix I)
(Golub and Pittman 2003). Due to the short duration of phase I experiments, dehydration
was not an issue; during phase II experiments dehydration was prevented by intravenous
administration of fluorescent and phosphorescent probes dissolved in phosphate buffered
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saline (PBS), as well as a continuously infused anesthetic (Saffan, ~0.3 ml/hr). A
prophylactic antibiotic, 60 mg tetracycline/L drinking water (Polyotic, Fort Dodge
Animal Health, Fort Dodge, IA, Lot # 010805) was administered for seven days after the
initial intervention to prevent mortality from suppurative pneumonia (Busch, Lauhala et
al. 1984). To assess and prevent undue distress, discomfort, or pain, animals were
monitored daily for one week after the intratracheal instillation, and scored using the
“Modified distress scoring sheet” (Lloyd and Wolfensohn 1999) (Appendix II) a
predictor of animal mortality; it was not necessary to euthanize any animal due to
distress.
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Figure 5. Sprague-Dawley male vs. female growth curve.
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Anesthesia
Induction of anesthesia for the initial intervention and phase I experiments was
accomplished by placing animals in an induction chamber (Anesthetizing box, Harvard
Apparatus) with 4% Isoflurane (AErrane, Lot # N009B310, Baxter, Deerfield, IL) and
96% oxygen, administered with a gas vaporizer (Quantiflex VMC Small Animal
Anesthesia Machine and VIP 3000 Veterinary Anesthesia Vaporizor, MDS Matrx,
Orchard Park, NY). The animals were then orally intubated and placed on a small-animal
pressure controlled ventilator (RSP1002, Kent Scientific Corp., Litchfield, CT), receiving
maintenance anesthesia of 2% Isoflurane (Waynforth and Flecknell 1992) and 98%
oxygen.
For the terminal microcirculatory experiments (phase II), animals were initially
anesthetized with a combination of Ketamine (75 mg/kg) and Acepromazine (2.5 mg/kg)
(Waynforth and Flecknell 1992). Maintenance of anesthesia throughout the experiment
was accomplished using intravenous (i.v.) Saffan (Alphaxolone 9 mg/ml and
Alphadolone 3 mg/ml, Schering-Plough Animal Health, Hertfordshire, England, Lot
20081) at an initial rate of 0.3 ml/hr (~0.2 mg/kg/min) (Waynforth and Flecknell 1992),
which was titrated to maintain a mean arterial pressure of 95-105 mmHg.
Following the terminal experiments, animals were euthanized by administering Euthasol
(Pentobarbital 390 mg/ml and Phenytoin 50 mg/ml, Delmarva Laboratories, Inc.,
Midlothian, VA) at a dose of 0.4 ml/kg (~150 mg/kg) (Goldberg and Henry 2000).
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Tracheal and vascular cannulations
A set of vascular and tracheal cannulae were made from various sizes of polyethylene
(PE) tubing (Figure 6). Endotracheal tubes (ETT) were made from PE 190 tubing, 6.5
cm long, with a teardrop shaped bulb placed ~2 cm from one end to seal the airway at the
vocal cords, as described by Smith et al (2004). A tracheostomy tube was made from a 5
cm section of PE 240 tubing.
Both the initial intervention and phase I required oral endotracheal intubation. Following
induction anesthesia, the vocal cords were visualized using a laryngoscope with a
modified Miller # 0 fiber optic blade (Welch Allyn, Skaneateles Falls, NY), while the
ETT with stylet was inserted into the trachea between the vocal cords during inspiration
(Costa, Lehmann et al. 1986; Smith, Tiba et al. 2004). The laryngoscope and stylet were
removed, the animal placed on mechanical ventilation, and correct ETT placement
verified by observing the chest rise and fall in synchrony with the ventilator. A
tracheostomy tube was placed during phase II experiments to maintain a patent airway,
decrease work of breathing, and allow port of entry for inspiratory gases.
The right femoral artery was cannulated for arterial blood gas (ABG) samples during
phase I experiments (Waynforth and Flecknell 1992). In phase II experiments, the right
external jugular vein and left common carotid artery were cannulated and used for
measurements of central venous pressure (CVP) and systemic arterial pressure (AP),
respectively. The measurements were collected at 100 Hz using pressure transducers
connected to a high-speed data acquisition system (MP150, BIOPAC Systems, Inc.,
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Goleta, CA) via a RJ-11 cable, transducer connector interface (TCI-105, BIOPAC), and
general purpose transducer amplifier (DA100C, Biopac). This acquisition system was
connected to a personal computer (PC) equipped with a digital chart recorder
(AcqKnowledge software, v3.7.3, BIOPAC). In addition, the jugular venous line was
used for continuous infusion of i.v. Saffan, and the carotid arterial line was used for ABG
sampling. The right femoral vein was also cannulated during phase II experiments for
i.v. injections of various experimental solutions. Patency of vascular cannulae was
maintained with either a heparin lock (20 units of heparin/ml of normal saline) or
continuous infusion.
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Figure 6. Vascular and tracheal cannulae (A. Femoral arterial (PE 50-20-10), B.
Carotid artery (PE 90-50), C. Femoral venous (PE 50), D. External jugular venous
(PE 90), E. Endotracheal (PE 190 with "bulb"), and F. Tracheostomy (PE 240)).
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Initial intervention: Elastase/vehicle instillation
Lyophilized porcine pancreatic elastase (Elastin Products Company, Inc., Owensville,
Missouri, EC134, 135 units of activity/mg of protein, Lot 52669) was dissolved in normal
saline to give a concentration of 400 international units/ml of saline, and was
administered at a dose of 80 units/100 g body mass (0.2 ml/100 g). Animals in the
vehicle control group received an equivalent volume of normal saline (0.2 ml/100 g)
Following placement of an ETT, the animals remained hanging on the intubation board
and were allowed to rest for three minutes on the ventilator. At that point, they were
positioned on their left side at 60°, were temporarily removed from the ventilator, and
half of their total dose was instilled into the ETT via a 1-ml syringe equipped with a
sterile 20-gauge needle (Busch, Lauhala et al. 1984; Sato, Kato et al. 1990). The animals
were placed back on the ventilator for two minutes in order to 1) maintain anesthesia, 2)
ensure adequate ventilation and oxygenation, and 3) to assist in the distribution of the
elastase. Following rotation to the right, and instillation of the remaining dose of
elastase/vehicle, they were, again, placed on the ventilator for two minutes. At this point
they were taken off the ventilator, and thus anesthesia. The ETT was removed as the
animal awakened, and it was returned to its housing following a resumption of normal
activity and no signs of respiratory distress, as determined by a score of ≥ 12/19 on the
“Modified distress scoring sheet” (Lloyd and Wolfensohn 1999) for three hours.
Prophylactic antibiotics (60 mg tetracycline/L drinking water; Polyotic, Fort Dodge
Animal Health) were administered for seven days to prevent mortality from suppurative
pneumonia (Busch, Lauhala et al. 1984).
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Radiography
Ventral-dorsal (VD) and lateral chest radiographs were made of two animals, one
experimental and one control, in the Department of Animal Resources with the assistance
of a veterinary technologist and a veterinarian. These radiographs were made,
approximately 19 weeks after the initial intervention, on living animals while intubated
and anesthetized with Isoflurane, as previously described (“Anesthesia,” page 39), during
a “sigh” breath from the ventilator (with a maximal inspiratory pressure of 10 cmH2O).
Radiographs were taken using a Universal MP 300 X-ray unit used at a 40-inch distance
set at 2 milliamp-seconds as well as 50 and 48-kV peak, respectively, for VD and lateral
radiographs, resulting in an exposure time of 0.006 sec (Snider and Sherter 1977).

MHC isoform determination
The relative proportions of myosin heavy chain isoforms I, IIa, IIx/d, and IIb from each
muscle were determined using the sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) technique of Talamadge and Roy (1993), as modified by
Kinirons (2002).

Muscle biopsy and tissue processing
After being euthanized, the left vastus lateralis, gastrocnemius, soleus, and spinotrapezius
muscles were isolated and removed from the animals by open biopsy, weighed, placed in
a microcentrifuge tube, quickly frozen in liquid nitrogen and stored at -70° C. The frozen
muscles were later lyophilized, minced with scissors, homogenized with a mortar and
pestle, and placed in a cold extraction buffer (see Appendix IV, MHC extract solution)

45

(Zhang, Wright et al. 1997). Following agitation every ten minutes, at 4° C for 60
minutes, the samples were centrifuged at 10,000 G for 10 minutes. A small portion of the
supernatant, containing extracted MHC, was pipetted into microcentrifuge tubes and
stored at -70° C.
At a later time, the extracted muscle samples were brought to room temperature, mixed in
a vortex mixer, and the protein concentration assayed, based on the method of Bradford
(1976) using a microplate absorbance reader at a wavelength of 595 nm (Tecan Sunrise,
Phenix Research Products, Hayward, CA) calibrated with known concentrations of
bovine serum albumin (Figure 7). If necessary, samples were diluted with additional
extract solution to achieve a protein concentration of ~0.25 mg/ml and stored at -70° C.
On the day in which the SDS-PAGE was run, the diluted muscle samples were again
brought to room temperature, mixed in a vortex mixer, and combined with an equal
volume of sample buffer (see Appendix IV), yielding a final protein concentration of
~0.125 mg/ml. This sample was boiled for five minutes to help denature the protein, and
then cooled to room temperature prior to loading into the gel.
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SDS-PAGE
The SDS-PAGE procedure, briefly described below, is detailed in the PROTEAN II xi

Cell Instruction Manual, section 4.1: “Casting Discontinuous (Laemmli) Gels” (Bio-Rad
Laboratories, Hercules, CA).
The 8% SDS separating gel solution (see Appendix IV), immediately after addition of the
polymerizing agents, was injected between two glass plates in a casting stand to a height
of ~13 cm. This 0.75 mm thick gel was layered with ~1 cm 10% ethanol, and allowed to
set for at least 45 minutes. At this point, the ethanol was poured off, and Whatman #1
filter paper was used to dry between the glass plates. A 15-space comb was inserted
between each plate prior to injecting the 4% SDS stacking gel solution (Appendix IV) to
form the “wells” into which the muscle samples were injected. The stacking gel was
allowed to set for at least 60 minutes; the comb was gently removed, and each well was
individually and gently cleaned by an injection of the upper running buffer from a 5-ml
syringe and 23-gauge needle.
Twenty µl of each sample were slowly injected into a separate well, yielding ~2.5 µg of
protein per lane. The first and last wells were not used, and a standard (Precision Plus
Protein Standard, 161-0374, Bio-Rad) was placed in the middle to help identify the bands
of interest. The glass plate sandwich was then locked into a cooling core, and the upper
and lower buffer chambers were filled with their respective buffer solutions (see
Appendix IV), respectively. The central cooling core was placed in the lower buffer
chamber, and 400 µl of 2 β-mercaptoethanol were added to the upper buffer chamber.
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The lower buffer chamber, with the lid in place, was placed in the refrigerator, leveled,
and the electrodes plugged into the electrophoretic system power supply (Power Pac
1000, Bio-Rad). The electrophoresis unit ran at a constant voltage of 275 volts for ~30
hours (maximal current of 20 mA per gel for 90 minutes, followed by a maximum of 15
mA per gel for the remaining time).

Gel staining and analysis
Immediately after removal from the glass plates, each gel was placed in a fixative
solution (Appendix IV) for 20 minutes, rinsed twice with deionized water for 10 minutes,
and stained with silver (Silver Stain Plus Kit, 161-04149, Bio-Rad). After adequate
staining, the gels were placed in a stop solution (5% acetic acid) for 15 minutes, and
rinsed for again for five minutes. In each of the above steps, the gels were gently agitated
on a platform shaker (Innova 2000, New Brunswick Scientific Co., Inc., Edison, NJ).
Gels were removed from the rinse solution and immediately scanned with a highresolution scanner (Duoscan HiD, AGFA, Belgium). These images were saved onto a PC
and later analyzed offline with Gel-Pro Analyzer, MediaCybernetics, Silver Spring, MD),
which was used to determine the relative fraction of total MHC isoform expression.
Since each band, containing a different MHC isoform, was evaluated relative to other
bands in the same lane (muscle), differences in protein concentrations and staining
intensity between different lanes was not an issue. In addition, to make staining more
uniform, only one type of muscle was analyzed on a single gel, and the protein content
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per lane was uniform. Determination of MHC type from the stained gels was based on
the migration order, I > IIb, IIx, > IIa (Figure 8) (Talmadge and Roy 1993).
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Figure 8. MHC bands after SDS-PAGE and silver staining. MHC I has the greatest
electrophoretic mobility, followed by IIb, IIx and then IIa, with the least.
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Spinotrapezius muscle preparation
The spinotrapezius muscle was prepared as previously described (Gray 1973; Lash and
Bohlen 1987; Suzuki, Poole et al. 1995). After exposing the muscle through a dorsal,
midline incision, the layer of subcutaneous fat and connective tissue was gently removed,
while taking care not to damage the underlying muscle. Bleeding was prevented or
controlled by using a cautery, and the tissue was keep moist with frequent applications of
normal saline. Muscle length was measured on the lateral border of the spinotrapezius
muscle, from the origin on the thoracolumbar fascia to its insertion on the spine of the
scapula.
After the entire lateral border of the spinotrapezius muscle was gently separated from the
underlying latissimus dorsi muscle, and the penetrating vessels at the caudal end were
cauterized, an 8 cm, 28-gauge wire (~60 mg), in the shape of a horseshoe (Suzuki, Poole
et al. 1995), was sutured to the lateral border at 8-10 mm intervals using 5-0 silk sutures.
This “horseshoe” was then sutured to the muscle at 8-10 mm intervals as it was cut from
its caudal, and then medial origins; in this process, a medial feed arteriole was cauterized
as well. The wire horseshoe served as a rigid interface to attach the muscle to the force
transducer (Figure 9), and also kept the muscle flat, near its in situ position, on the
platform before and after muscle contractions.
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Figure 9. Spinotrapezius muscle on pedestal connected to force transducer and
covered by Saran film.
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Intravital microscope
During the data collection phase of the experiment, both transmission and episcopic
illumination images of the spinotrapezius preparation were continuously recorded from
an upright Zeiss ACM microscope (Carl Zeiss, Inc., Göttingen, Germany).
Transillumination and epifluorescent images were continuously recorded onto a video
cassette recorder (VCR; Panasonic AG 7350) using a charge-coupled device camera
(CCD-72, Dage MTI, Michigan City, IN); these images were visualized on a 20” video
monitor (Panasonic WV 5490). The light source for both fluorescence and
phosphorescence excitation was a Xenon flash lamp (Model FX-249, EG&G
Optoelectronics, Salem, MA), with an output of 0.5 J, duration of 3 µs, used at a
frequency of 100 Hz and 20 Hz, respectively.
For epifluorescence microscopy, used for blood velocity measures, a fluorescence filter
cube was used (Figure 10) (11001v2, Chroma Technology Corp., Rockingham, VT) with
an 1) excitation filter with a center wavelength at 470 nm and full bandwidth of 40 nm, 2)
dichroic, longpass beamsplitter with a cut-on wavelength of 495 nm, and 3) longpass
emission filter with a cut-on wavelength of 515 nm (Figure 11).
For phosphorescence microscopy, used for microvascular PO2 measures, a filter cube was
used with a 1) 430 nm bandpass excitation filter (430BP100, Omega Optical Inc.,
Brattleboro, VT), 2) dichroic, longpass beamsplitter with a cut-on wavelength of 510 nm
(FT510, Zeiss), and 3) an emission filter with a cut-on wavelength of 650 nm (Oriel
Corp., Stratford, CT).
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Figure 10. Flourescence filter cube (Chroma 11001v2).
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Phosphorescence quenching microscopy
Hardware
The microscope, excitation source and filter set were described above. Following
excitation at 10 Hz through a 32 µm square diaphragm, the emitted phosphorescence
signal from the spinotrapezius muscle was sent to a photomultiplier tube (model R1617,
Hamamatsu, Middlesex, NJ). Output from the photomultiplier was sent to a low-noise
current-to-voltage converter (model OP27EP, Analog Devices, Norwood, MA). That
signal was sent to both an analog-to-digital converter (AT MIO/6F5, National
Instruments, Austin, TX) in a PC, and it was monitored on an oscilloscope (model 723060, Tenma Test Equipment, Springboro, OH) to ensure that the signal was
approximately 8 volts (near the maximal input voltage of 10 V for the analog-to-digital
converter); this setup is diagramed in Figure 12 (Zheng, Golub et al. 1996).
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Figure 12. Schematic diagram of phosphorescence quenching microscopy setup.
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Palladium-porphyrin phosphorescence probe preparation
Preparation of the albumin-bound Palladium-porphyrin phosphorescence probe (10
mg/ml) was a multi-step process, whose details are included in Appendix III. In brief, it
included preparing a solution of bovine serum albumin, fraction V (Sigma-Aldrich, Inc.,
St. Louis, MO), to which palladium meso-tetra (4-carboxylphenyl) porphyrin (PdMTCPP; Oxygen Enterprises, Ltd., Philadelphia, PA) was bound. This solution was
dialyzed in polyvinylpyrrolidine (Sigma-Aldrich, Inc.) for ~24 hours to remove any
unbound Pd-MTCPP from the solution. The pH was adjusted to 7.3 – 7.5 with the
addition of Trizma base (Sigma-Aldrich, Inc.). The final product was filtered using a
sterilization filter unit (NALGENE Labware, Rochester, NY), pipetted into 0.5 ml
microcentrifuge tubes, immediately frozen in liquid nitrogen, and stored at -80° C.

Data acquisition and microvascular PO2 analysis
LabVIEW 4.01 (National Instruments) was used to acquire and process the signal from
the analog-to-digital converter at a sampling rate of 100 kHz. Twenty decay curves per
measurement, 400 points per decay curve, were normalized, averaged, and saved in
LabVIEW for off-line analysis.
Measuring PO2 using the phosphorescence quenching method is based on the relationship
between phosphorescence lifetime, τ, and PO2, using the Stern-Volmer equation:
Equation 4

1 / τ = 1 / τ 0 + k q PO 2
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where τ0 is the lifetime in the absence of oxygen (546 µs), and kq is the quenching
coefficient (3.06·10-4 µs-1·mmHg-1). Normalized, averaged phosphorescence decay
curves were analyzed using Origin 7.05 (OriginLab). Each curve was plotted on a semilogarithmic scale, and analyzed using a non-linear curve fitting equation, based on the
rectangular (R) distribution model of oxygen as developed by Golub et al (1997):
Equation 5
Y (t ) = A ⋅ YR (t ) + (1 − A) exp(−t / τ F )

where A is the fraction of the observed signal due to phosphorescence, (1-A) is the
fraction contributed by the tail of the excitation flash, τF is the lifetime of the residual
flash contribution, t is time in µs, and YR (t ) Equation 6 is the relationship between
phosphorescence decay rate and PO2 (k0 is 1/τ0, and δ is the half-width of the rectangular
distribution) (Golub, Popel et al. 1997).
Equation 6

[

]

(

)

YR (t ) = exp −(k 0 + k q PO 2 ) t sinh k qδ t / k qδ t

A representative plot, Figure 13, illustrates this relationship.
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Figure 13. Representative phosphorescence decay curve.
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Spinotrapezius oxygen consumption
Oxygen consumption of the spinotrapezius muscle was calculated based on Fick’s
principle, using spinotrapezius blood flow Q ST , and the arteriolar-venular oxygen content
difference (CaO2-CvO2) as described in Equation 7:
Equation 7

VOST = Q ST (CaO 2 − CvO 2 ) ,
2

where CO2 is the oxygen content of blood (ml of O2/dl of blood), and the subscripts “a”
and “v” refer to arteriolar and venular blood, respectively. Measurement of blood flow is
discussed in the following section “Blood flow.”

Oxygen content
CO2 includes oxygen both bound to hemoglobin and dissolved in blood, as defined in
Equation 8:
Equation 8
CO 2 = SO 2 [ Hb]CHb + αO 2 ⋅ PO 2 ,

where SO2 is the fractional oxygen saturation of hemoglobin, [Hb] is hemoglobin
concentration (g/dl), CHb is the oxygen binding capacity of hemoglobin (1.39 ml of O2/g
of Hb), αO2 is the solubility coefficient of oxygen in whole blood (0.003 ml of
O2/dl·mmHg), and Po2 is the partial pressure of oxygen (mmHg), which was determined
using phosphorescence quenching microscopy.
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Hemoglobin concentration, [Hb], was calculated from Equation 9:
Equation 9
[ Hb] = tHb − [tHb ⋅ (COHb + MetHb)]

where tHB is total hemoglobin concentration, COHb and MetHb are the fraction of tHb
that is either carboxyhemoglobin or methemoglobin, respectively. It was assumed that
spinotrapezius arteriolar and venular [Hb] were equivalent to carotid artery [Hb]. This
end result is the quantity of hemoglobin available for binding to oxygen.
SO2 was calculated from microvascular Po2, based on the rat oxyhemoglobin dissociation
curve (
Figure 1, page 7) using the Hill model and Mathcad 2000 (MathSoft, Inc., Cambridge,

MA):
Equation 10

SO 2 = SO 2

max

⋅

(P

)

virtual n
O2

(

P 50 n + PO 2virtual

)

n

where SO 2max is 100, the Hill coefficient, n, is 2.7 (Kunert, Liard et al. 1996), and the P50
for rat blood, based on previous studies (Hall 1966; Lahiri 1975; Teisseire, Soulard et al.
1984; Kunert, Liard et al. 1996; Eichelbronner, Sielenkamper et al. 1999; Zinchuk and
Dorokhina 2002), is 36 mmHg. “Virtual” Po2 ( PO2virtual ), which is based on standard
temperature, pH and Pco2 (via base excess, BE), was calculated from microvascular Po2
measures ( PO 2measured ) according to Equation 11:
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Equation 11
PO 2virtual = 10 (log10 PO2

measured

+ 0.48 ( pH − 7.4 ) − 0.024 (Tm −37 ) − 0.0013⋅ BE

)

that combines the equations of Severinghaus (1966). Based on the work of Lash and
Bohlen (1987), arteriolar pH was assumed to be equivalent to that of carotid arterial
blood, and venular pH was assumed to be 0.06 (the mean arterial-venous pH difference)
(Teisseire, Soulard et al. 1984; Powell, Machiedo et al. 1991) less than arterial pH.
Spinotrapezius muscle temperature was used as spinotrapezius blood temperature (Tm).
Base excess (BE), which has only a minor impact on the oxyhemoglobin dissociation
curve, was assumed to be equivalent in both arterial and venous blood.

Blood flow
Spinotrapezius blood flow ( Q ST ), of both the primary arteriole and venule, was
calculated from Equation 12, which relates cross-sectional area of the blood vessel and
average blood velocity:
Equation 12
2

d 
Q ST = π   v
2
where d and v are the diameter and mean blood velocity, respectively. The diameter was
determined during off-line analysis by measuring the internal width, perpendicular to the
direction of blood flow, of the vessel on a video monitor, which was calibrated with a
stage micrometer (Bausch & Lomb, Rochester, NY). Using a Neofluar 40X/N.A 0.75
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water immersion objective (Model 46-07-52, Carl Zeiss, Inc.), 1.0 mm on the video
monitor was equivalent to 0.51 µm on the microscope stage. The microscope was
focused on the median plane of the vessel.
Blood velocity

As the velocity profile (Figure 14) demonstrates, blood velocity decreases away from the
longitudinal axis of the vessel (R0). Pittman and Ellsworth described red blood cell
velocity with Equation 13 (Pittman and Ellsworth 1986),
Equation 13


 r 2 
v ( r ) = v0 1 − B 2 
 R 

where r is the radial distance from the axis, v0 is maximal blood velocity (r = 0), B
describes the bluntness of the profile, which ranges from 0 (plug flow) to 1 (Poiseuille
parabolic flow), and R is the vessel radius. This equation forms the basis for deriving
many of the equations used below for both venular and arteriolar velocity calculations.
To help determine blood velocity, a 0.1 ml solution (concentration 4.5·108 particles/ml)
of 2.0 µm FluoSpheres, fluorescent microspheres (F-8827, lot 69A1, Molecular Probes,
Inc., Eugene, OR), were injected via the jugular venous catheter for each time point
measured (Rovainen, Wang et al. 1992; Vovenko, Golub et al. 2002). To prevent
hypotensive episodes due to the anti-aggregate compound, Tween-20, the FluoSpheres
were prepared as described in Appendix V. For blood velocity measurements, these
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FluoSpheres were briefly excited by a 100 Hz flash illumination. Since the VCR
captures video frames at a rate of 30 Hz, each microsphere produced a train of
approximately three particle images on a single video frame.
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Figure 14. Longitudinal section of vessel, demonstrating bluntness of the velocity
profile (B), vessel radius (R), longitudinal axis of vessel (R0), and middle one-third of
vessel (W).

67

Depth of field

The depth of field (D) for the objective was calculated to be 0.62 µm using Equation 14
and Equation 15, from Slayter (1970),
Equation 14

D=

0.61λ cos α
n sin 2 α

Equation 15

 N.A. 

 n 

α = sin −1 

where λ is the emission wavelength from the FluoSphere, 515 nm, α is the aperture, or
vertex angle, 34°, and n is the refractive index of water, 1.337 (Figure 15). Thus,
microspheres within ± 0.31 µm of the image plane will appear in focus. Whether the 2µm diameter fluorescent particles were in focus was determined subjectively by the
quality of the image, and objectively by the size of the microsphere image on the video
monitor; “in-focus” microspheres have an on-screen diameter of ~4 mm (see above).
This method of determining if RBCs or microspheres are in the median plane has been
validated by Bishop et al (2001) and Tangelder et al (1986).
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Figure 15. Depth of field (D) and aperture angle (a).
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Venular blood velocity

In venules, where velocity is slower, maximal blood velocity was determined. The
distance between in-focus microspheres on the median plane of the vessel and within the
middle one-third of the vessel (W) (Figure 16) allowed for determination of particle
(fluorescent microsphere) velocity (vp) during off-line analysis, using Equation 16:
Equation 16
 dt 


n − 1
vp = 
t

where dt is the total distance between the first and last image of a single particle captured
in a video frame, n is the number of times a microsphere appears in that frame, and t is
0.01 seconds (the time between flashes for 100 Hz excitation). The average velocity,
weighted by particle frequency ( v * ), was determined by averaging the velocities of
approximately 10 different particles (vp). The result of the arithmetic average of the
particle velocities is a value that is weighted by particle velocity, since the number of
particles passing through the observation region is proportional to their individual
velocities.
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Figure 16. Cross section of vessel, demonstrating median plane, vessel radius (R)
and the middle one-third of vessel (W).
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Mean blood velocity ( v ) was calculated from v * using Equation 17 (Pittman 2004),
Equation 17
2


 1 − B  1 − B  W   



 
2  
3  2 R   
*

v =v 
2
4

B2  W  
2B  W 
 1 − 3  2R  + 5  2R  

 






Observing venules in the rat spinotrapezius muscle, Bishop et al (2001) reported values
for B ranging from 0.9 to 1.1; thus, my calculations will assume that B is 1, Poiseuille
flow. In addition, W/2R (Figure 16) was arbitrarily set to be 0.33.
Arteriolar blood velocity

In arterioles, the blood velocity was often so fast that, at a 100-Hz flash rate, centerline
microspheres often appeared only once, and thus, their velocity could not be calculated.
When this occurred, a slightly different methodology and equation were used. Instead of
measuring central particle velocities, individual particle velocities (vp) were determined
on the median plane outside of the center one-third of the vessel, the area excluding W
(Figure 16). Again, averaged velocity, weighted by particle velocity ( v * ) was
determined by averaging the velocities of approximately 10 different particles.
In this case, assuming B = 1, mean blood velocity was calculated using Equation 18
(Pittman 2004),
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Equation 18
2



W  1 W  
1
1
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 3
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5
W 2  W  1  W  
 8
  15 − 2 R + 3  2 R  − 5  2 R   
  



 

This equation assumed that the depth of field was much less than the radius of the vessel;
this was an appropriate assumption given that the depth of field was 0.62 µm and the
radius was approximately 50 µm.
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Muscle Contraction and Contractile Measures
The muscle contractions were initiated via a muscle stimulator (A310 Accupulser pulse
generator and A360 high voltage stimulus isolator, World Precision Instruments, Inc.,
Sarasota, FL) connected to the exteriorized spinotrapezius muscle by two silver/silver
chloride electrodes. The electrodes were fabricated from thin strips of an electrically
conductive polymer coated film (114-26 B, Creative Materials, Inc., Tyngsboro, MA) and
insulated 20-gauge wire connected by an electrically conductive epoxy (GPC 251,
Creative Materials, Inc.).
Muscle force was measured with a Grass force-displacement transducer (model FT03C,
Grass Instrument Co.), which has a linear sensitivity of 2 mg to 10 kg and a resonant
frequency of 85 Hz; the transducer previously demonstrated a linear relationship between
voltage and mass (Figure 17). Twenty-gauge wire was used to connect the wire support
of the spinotrapezius muscle directly to the force transducer (Figure 9). The force
transducer was attached to a tension adjuster mounted on the animal platform, which was
used to optimize muscle length (Lo) during whole muscle isometric twitch contractions.
During preliminary tests, it was determined that Lo occurred at a preload of ~3 g, which is
in agreement with the results of Suzuki et al (1995).
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Figure 17. Force transducer calibration curve
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Signals from the force transducer were sent to a general purpose transducer amplifier
(DA-100C, BIOPAC Systems, Inc., Goleta, CA; gain of 200 and with a 10 and 100 Hz
low pass filter) and high-speed data acquisition system (MP150, BIOPAC) via a six-pin
Grass cable and transducer connector interface (TCI-100, BIOPAC), and then to a
desktop computer for continuous on-line data acquisition at a rate of 100 Hz
(AcqKnowledge software, v3.7.3, BIOPAC).
Peak force measurements were obtained during 200 msec stimulation at 80 Hz. In
addition, muscle force was continuously acquired during a three-minute muscle
stimulation protocol. This protocol involved contractions at a rate of one contraction per
second; each contraction was stimulated by a 9-pulse (0.5 msec pulse duration) constantfrequency train delivered over 200 msec (40 Hz) (Figure 18), which was verified using a
digital oscilloscope (TDS 2002, Tektronix, Beavertown, OR). From this recording,
isometric muscle “work” and fatigue index were calculated.
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A = Pulse width (500 µsec)
B = Pulse frequency (40 Hz)
C = Train frequency (1 Hz)

A

B

C

500 µsec

50 msec

500 msec

Figure 18. Stimulation protocol, where A) is an individual pulse, B) is a train of nine
individual pulses, and C) is series of pulse trains (note the different time scales).
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The force-time integral (FTI):
Equation 19
180

W =

∫ F ⋅ dt
0

was used to quantify isometric muscle work (W) based on force (F) and time (Rome and
Kushmerick 1983; Russ, Elliott et al. 2002). FTI was calculated from the force curves
(Figure 19) using Origin 7.05 (OriginLab Corp., Northhampton, MA), and normalized to
the estimated muscle cross-sectional area (CSA) in cm2:
Equation 20

CSA =

m
.
ρ ⋅ L0

where m is mass in grams, ρ is density, assumed to be 1.05 g·cm-2 (Rome and
Kushmerick 1983), and L0 is muscle length in centimeters, to give a final quantity in
N·s/cm2.
Fatigue index (FI) (Burke, Levine et al. 1973) was calculated as the percent decline in
force from its peak to the last contraction of the three-minute protocol (Equation 21)
(higher values mean less fatigue).
Equation 21
FI = 100 ⋅

Fterminal
Fpeak

78

0.10

Force (N)

0.08

0.06

0.04

0.02

0.00
0

30

60

90

120

150

180

Time (sec)

Figure 19. Representative spinotrapezius force tracing, from which force-time
integral and fatigue index were calculated.
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Specific protocols
The following details the experimental protocol for each phase. For all animals, PaO2 and
PaO2/FIO2 ratio, an index of respiratory function (Sheridan, Zapol et al. 1999), was used to
assess the degree of hypoxemia and indirectly quantify the severity of emphysema or
other respiratory pathology. While a normal PaO2/FIO2 ratio should be ~500 (100/0.21),
values of less than 300, 200, or 100 indicate a mild, moderate, or severe gas exchange
impairment, likely due to intrapulmonary shunting and lung injury (Artigas, Bernard et
al. 1998).

Phase I
Experiments were conducted on groups of animals 4, 8, 12, 16, or 20 weeks following the
initial instillation of either elastase or saline to help determine the time course of any
changes in arterial blood gases or transformation of muscle fiber types. After initial
anesthesia and oral endotracheal intubation (described on pages 39 and 40, respectively),
the animal was placed on a small animal ventilator set for a FIO2 of 0.21 (room air),
respiratory rate (RR) of 60 breaths per min (bpm), and inspiratory pressure of 10-12
cmH2O. Pilot testing revealed that these settings resulted in normal ventilation as
determined by arterial pH and PCO2.
Following 20 minutes of recovery and equilibration on the ventilator, and after femoral
arterial cannulation, a normoxic arterial blood sample was withdrawn into a 100 µl
capillary tube and analyzed in both a blood gas analyzer (ABL 705, Radiometer,
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Denmark) to measure blood gas values (pH, PaO2, PaCO2), electrolytes (K+, Na+, Ca+2, and
Cl-) and metabolites (glucose and lactate), and a co-oximeter (OSM 3 Hemoximeter,
Radiometer) to measure tHb, COHb, MetHb, oxy-Hb, deoxy-Hb, and SO2. To simulate a
fall in PaO2 (hypoxic condition), as occurs during whole body exercise in patients with
emphysema, the FIO2 was reduced to 0.15 and the animal given 20 minutes to equilibrate
before withdrawing a hypoxic arterial blood sample.
At this point the animal was euthanized and the right spinotrapezius and soleus muscles
were immediately removed and processed as previously described (page 44).

Phase II
For microcirculatory and muscle physiology experiments, animals were randomized
approximately 62 weeks after elastase or saline instillation. The force transducer and
pressure transducers were calibrated at two points prior to each experiment. After initial
anesthesia and cannulations, the spinotrapezius muscle was prepared as previously
described (page 10), and the animal was transferred to the thermostatic animal platform.
The spinotrapezius muscle was positioned, ventral surface facing up, on the viewing
pedestal of the platform, connected to the force transducer, moistened with normal saline
and the covered with Saran film (S.C. Johnson & Sons, Inc. Racine, WI) to prevent
desiccation and minimize atmospheric gas exchange.
After the platform was securely placed on the microscope, carotid arterial and jugular
venous cannulae were connected to their respective pressure transducers, and muscle
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tension adjusted to Lo; these parameters were continuously recorded on an electronic
chart recorder (Biopac), as previously described, for the duration of the experiment.
After peak force was measured from a twitch contraction (80 Hz for 200 msec), capped
Tygon tubing was placed over the tracheostomy tube to deliver a FIO2 of either 0.21 or
0.40 at a rate of 0.4 liters per minute. The animal was given at least 15 minutes to
recover from surgery and equilibrate to its FIO2. In the meantime, the Pd-MTCPP and
FluoSphere solutions (Appendices III and V, respectively) were warmed to greater than
room temperature, and the primary feed arteriole and venule were located under the
microscope. Prior to baseline microvascular measures and the muscle contraction
protocol, an arterial blood gas sample was drawn from the carotid artery and immediately
analyzed (as described above), the Pd-MTCPP solution was injected via the femoral vein,
and vital signs (body temperature, heart rate, systolic and diastolic blood pressure, and
mean arterial pressure were measured. A continuous video recording of the
microcirculation was made.
Baseline arteriolar and venular PO2 measurements were made using the phosphorescence
quenching method (page 54), followed by a 0.1-0.2 ml injection of FluoSpheres via the
femoral vein, and blood velocity and diameter recorded as described above (“Blood
flow,” page 63). Immediately after a three-minute stimulation protocol, as described
above (“Muscle Contraction and Contractile Measures,” page 73), another 0.1-0.2 ml
injection FluoSpheres was administered and blood velocity, vessel diameter, and
microvascular PO2 measurements were made, as well as five minutes after the end of the
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contraction. The FIO2 was then changed to either 0.21 or 0.40, and the animal given 15
minutes to recover and equilibrate. Baseline vital signs and microvascular measures were
taken again, and the stimulation protocol and microvascular measures were repeated as
previously described.
After the animal was euthanized, the spinotrapezius muscle was removed and weighed, a
thoracic necropsy was performed, and the heart and lungs removed en bloc, inflated and
photographed.

Statistical Analysis
Data in text and tables are presented as mean ( x ) and standard deviation (SD), and
graphic data are presented as mean values with bars or bands representing a 95%
confidence interval. JMP version 4.0.4 (SAS Institute, Inc., Cary, NC) was used to
perform significance tests (analyses of variance on multiple factors and t-tests on two
independent means); actual p values are reported with the level of significance set at 0.05.
Reporting in this manner is in accordance with established recommendations (Streiner
1996; Curran-Everett, Taylor et al. 1998), as well as the American Physiological
Society’s guidelines (Curran-Everett and Benos 2004).

Results

Phase I
Experimental animals
During pilot studies, as the instillation technique was being developed, five consecutive
animals died during or immediately after the instillation procedure (one elastase, four
saline); Poole (2002) had warned of this possibility. However, for no known reason,
these were the last procedure-related fatalities. No other animals died prior to the final
experiment.
Sixty-one animals were used in phase I, and data were available for 56 (two were taken
by the Division of Animal Resources for testing, two died during the terminal
experiment, and one animal is unaccounted for). As seen in Table 3, Student’s t-test
found no differences between elastase and saline groups with regard to age at instillation
(p = 0.57), initial or final body mass (p = 0.75 and 0.78, respectively), or weight gain (p =
0.96) between initial instillation and the terminal experiment. Likewise, a two-way
analysis of variance (ANOVA) found no effect (p = 0.18) for baseline body mass with
respect to experimental group (elastase vs. saline) and time after instillation (weeks)
(Table 4).
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Figure 20 illustrates the change in mass between groups over time. In addition, soleus
and spinotrapezius muscle masses were equivalent between experimental groups (p =
0.31 and 0.74, respectively). Over time, the only difference was found in the
spinotrapezius muscle, which was lighter at four weeks after instillation than at eight, 12,
16, or 20 weeks (Figure 21) (p < 0.01 to 0.04).
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Table 3. Baseline characteristics.
Group

n

Age at instillation Initial mass

Final mass

Difference

(weeks)

(g)

(g)

(g)

Elastase 30

10.8 (SD 0.7)

213.7 (SD 16.2)

266.4 (SD 31.9)

52.8 (SD 32.8)

Saline

25

10.7 (SD 0.7)

214.9 (SD 11.3)

268.5 (SD 22.8)

53.6 (SD 24.5)

Total

55

10.8 (SD 0.7)

214.2 (SD 14.1)

267.4 (SD 27.9)

53.2 (SD 29.0)

Table 4. Final body mass (g) for each time interval.
Group

4 weeks

8 weeks

Elastase

234 (SD 10.9) 275 (SD 12.0) 268 (SD 10.1) 280 (SD 10.9) 278 (SD 12.0)

Saline

267 (SD 10.9) 257 (SD 15.4) 276 (SD 12.0) 265 (SD 12.0) 273 (SD 10.9)

Total

250 (SD 7.7)

266 (SD 9.8)

12 weeks

272 (SD 7.8)

16 weeks

272 (SD 8.1)

20 weeks

275 (SD 8.1)
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Figure 20. Growth curve.
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Figure 21. Soleus and spinotrapezius muscle masses over time.
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To qualitatively assess whether or not the elastase instillation was producing emphysema,
two animals had ventral-dorsal (Figures 22 and 23) and lateral chest radiographs (Figures
24 and 25) taken approximately 19 weeks after the instillation of either elastase or saline;
it is fairly obvious that the rostral-caudal, lateral, and ventral-dorsal dimensions are larger
in the elastase instilled animal, consistent with emphysema. Arterial PaO2 and PaO2/FIO2
ratio were used to quantitatively determine the severity of emphysema and the resulting
hypoxemia (refer to “Arterial blood gases,” page 91).
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Figure 22. Ventral-dorsal chest radiograph of saline instilled rat.

Figure 23. Ventral-dorsal chest radiograph of elastase instilled rat.
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Figure 24. Lateral chest radiograph of saline instilled rat.

Figure 25. Lateral chest radiograph of elastase instilled rat.
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Arterial blood gases
With the exception of arterial PO2, PaO2/FIO2 ratio, and glucose and lactate concentrations,
arterial blood gas analysis revealed no differences between groups (elastase vs. saline)
with regard to blood gases, acid-base status, hemoglobin, or electrolytes breathing either
FIO2 0.21 (Table 5, Figure 26), or FIO2 0.15 (Table 6, Figure 27).
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Table 5. Phase I arterial blood gas data on FIO2 0.21.
Elastase

pH

Saline

p value

7.43 (SD 0.03)

7.44 (SD 0.03)

0.49

PaCO2 (mmHg)

40 (SD 3.4)

38.5 (SD 4.3)

0.07

PaO2 (mmHg)

77 (SD 10.7)

90 (SD 21.6)

<0.01

365 (SD 51)

427 (SD 103)

<0.01

HCO3- (mmol/l)

26 (SD 0.9)

26 (SD 1.5)

0.08

SaO2 (%)

93 (SD 4.3)

94 (SD 6.7)

0.51

tHb (g/l)

140 (SD 7.4)

142 (SD 6.8)

0.19

K+ (meq/l)

3.8 (SD 0.3)

3.8 (SD 0.2)

0.78

Na+ (meq/l)

137 (SD 1.6)

136 (SD 1.4)

0.40

Ca+2 (meq/l)

2.2 (SD 0.2)

2.1 (SD 0.2)

0.57

Cl- (meq/l)

99 (SD 2.4)

99 (SD 1.8)

0.71

Glucose (mg/dl)

224 (SD 31.2)

250 (SD 59.6)

0.04

Lactate (mmol/l)

1.0 (SD 0.4)

1.5 (SD 1.2)

0.04

PaO2/FIO2

93

Saline
Elastase

120
100

PaO2

80
60
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Figure 26. Arterial PO2 at 4, 8, 12, 16, and 20 weeks; FIO2 = 0.21.
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Table 6. Phase I arterial blood gas data on FIO2 0.15.
Elastase

pH

Saline

p value

7.42 (SD 0.07)

7.44 (SD 0.04)

0.31

PaCO2 (mmHg)

41 (SD 8.2)

39 (SD 4.3)

0.22

PaO2 (mmHg)

57 (SD 9)

67 (SD 12)

<0.01

377 (SD 61)

449 (SD 77)

<0.01

HCO3- (mmol/l)

26 (SD 2.1)

26 (SD 1.3)

0.75

SaO2 (%)

84 (SD 12.3)

90 (SD 7.7)

0.06

PaO2/FIO2

tHb (g/l)

139 (SD 7)

142 (SD 7)

0.12

K+ (meq/l)

4.0 (SD 0.3)

4.1 (SD 0.2)

0.31

Na+ (meq/l)

136 (SD 2)

136 (SD 2)

0.65

Ca+2 (meq/l)

2.2 (SD 0.2)

2.2 (SD 0.2)

0.51

Cl- (meq/l)

99 (SD 2)

99 (SD 2)

0.51

Glucose (mg/dl)

225 (SD 58)

233 (SD 74)

0.66

Lactate (mmol/l)

1.3 (SD 0.9)

1.0 (SD 0.5)

0.30
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Figure 27. Arterial PO2 at 4, 8, 12, 16, and 20 weeks; FIO2 = 0.15.
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MHC isoforms
SDS-PAGE (Figure 28) was used to differentiate the various MHC isoforms, and a
densitometric analysis (Figure 29) was used to determine the relative proportions of each.
The only statistically significant difference in MHC isoforms between experimental
groups was a decrease in spinotrapezius MHC IIx, which was lower in the elastase group
(p = 0.01); however, the slight increases in other MHC isoforms were not significant
(Table 7). A two-way ANOVA for each MHC isoform found no interaction between
experimental group (elastase vs. saline) and age (14, 18, 22, 26, or 30 weeks old) (p =

0.08 to 0.83). However, it did reveal differences in soleus muscle MHC expression with
age for types I, IIa, and IIb (p = 0.0002, 0.05, and 0.006, respectively), but not IIx (p =
0.58) (Figure 30). In addition, spinotrapezius muscle MHC expression of type I, IIa, and
IIx changed with age (p = 0.03, <0.01, and 0.02, respectively); there were no differences
in IIb expression between age groups (p = 0.25) (Figure 31).
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Figure 28. Representative soleus SDS-PAGE with arrows at reference molecular
weights and MHC bands (~200 kDa). A, C, and D are 22, 18, and 26 wk old saline
instilled animals, B is a 22 wk old elastase instilled animal.
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Figure 29. Representative densitometric analysis used to determine proportions of
MHCs I, IIa, IIb, and IIx. Curves A – D correspond to the lanes labeled A – D in
Figure 28.
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Table 7. Percentage of MHC isoforms in elastase vs. saline instilled animals for all
age groups.
Elastase (n = 21)

Saline (n = 13)

p value

Soleus m.
I

9% (SD 1)

9% (SD 1)

0.69

IIa

10% (SD 6)

11% (SD 9)

0.86

IIx

63% (SD 7)

62% (SD 10)

0.77

IIb

18% (SD 6)

18% (SD 4)

0.88

I

17% (SD 7)

16% (SD 7)

0.55

IIa

10% (SD 12)

6% (SD 4)

0.35

IIx

40% (SD 12)

51% (SD 9)

0.01

IIb

33% (SD 9)

27% (SD 7)

0.07

Spinotrapezius m.
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Figure 30. Soleus muscle MHC proportions by age.
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Figure 31. Spinotrapezius muscle MHC proportions by age.
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Phase II
Experimental animals
There was no difference in body mass between elastase and saline groups ( x = 294 g (SD
37) vs. 296 g (SD 22), respectively; p = 0.15). In addition, there were no differences in
baseline vital signs between groups (Table 8). A matched pairs analysis also revealed no
differences in heart rate (HR), respiratory rate (RR), mean arterial pressure (MAP), or
body temperature between the exercise bouts on FIO2 0.21 versus 0.40 (p = 0.87, 0.42,
0.71, and 0.57, respectively), which indicates that the physiological conditions under
which the animals performed each exercise bout were similar.
Initially, injection of 0.5 ml FluoSpheres caused a rapid and dramatic drop in blood
pressure, severe enough to lead to death in a few preliminary experiments. Smaller doses
(0.1 ml) still led to a substantial decline in blood pressure, which took several minutes to
return to baseline (Figure 32). Eventually, it was determined that the anti-aggregation
agent, Tween-20, was responsible (Figure 33).
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Table 8. Baseline vital signs on FIO2 0.21 and 0.40.
Elastase
FIO2

0.21

p value

0.40

0.21

0.40

285 (SD 66)

333 (SD 59)

327 (SD 65)

E vs. S
0.21
0.29

57 (SD 12)

63 (SD 31)

67 (SD 10)

0.35

92 (SD 15)

97 (SD 11)

97 (SD 15)

0.51

37.1 (SD 0.9) 37.1 (SD 0.7) 36.5 (SD 1.0)

36.5 (SD 0.9)

0.32

HR
297 (SD 51)
(beats/min)
RR
81 (SD 28)
(breaths/min)
MAP (mmHg) 92 (SD 14)
Body
temp. (° C)

Saline
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Figure 32. Arterial blood pressure tracing, demonstrating a dramatic hypotensive
episode with each injection of FluoSpheres without Tween removed.
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Figure 33. Arterial pressure tracing, demonstrating no hypotension after injection
of either 1) FluoSpheres with Tween removed, or 2) normal saline, but significant
hypotension when supernatant from diluted and centrifuged FluoSpheres is
injected.
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Lung pathology
Due to the surprisingly low systemic PaO2 values from phase I as well as anecdotal
reports throughout this and other research universities, the lungs from each animal were
grossly necropsied to determine if the animal had a lung pathology (i.e., Rat respiratory
virus) other than elastase-induced emphysema. No animal had normal looking lungs,
and, if anything, the lungs from the saline group (Figure 34) looked even “less healthy”
than those from the elastase group (Figure 35).
There does not appear to be a close relationship between severity of lung injury and PaO2,
although the animal with the highest PaO2 (Figure 35, B) appears to have a segmental
(dorsal caudal and dorsal cranial) pattern of consolidation as opposed to the other lungs
which show a more diffuse infiltration. Although not entirely obvious from these figures,
there did appear to be a consistent pattern in which the right dorsal-caudal and dorsalcranial segments demonstrated more infiltrate, with relative sparing of the left lung, and
more medial and ventral segments of both the cranial and caudal lobes.
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Figure 34. Lungs from necropsy of saline instilled animals, which had the following
PaO2's (mmHg): A) 70, B) 96, C) 49, D) 79, and E) 62.
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Figure 35. Lungs from necropsy of elastase instilled animals, which had the
following PaO2's (mmHg): A) 64, B) 66, C) 66, D) 59, E) 49, and F) 72.
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Arterial blood gases
Unfortunately, due to the lung pathology so prevalent in the animals in this study, both
the elastase and saline groups were almost equally hypoxemic ( x PaO2 62 (SD 6.6) vs. 69
(SD 17.1), respectively with FIO2 0.21, p = 0.36), although on room air, only the elastase
group had a PaO2/FIO2 < 300 (Table 9). However, both groups had a PaO2/FIO2 < 300
when breathing FIO2 0.40 (Table 10), indicating a mild gas exchange impairment. In fact,
only one animal out of the 14, from the control group, had a room air PaO2 of > 80
mmHg.
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Table 9. Phase II arterial blood gas data on FIO2 0.21.

pH

Elastase (n = 8)

Saline (n = 6)

p value

7.44 (SD 0.04)

7.40 (SD 0.07)

0.17

PaCO2 (mmHg)

35 (SD 6.1)

43 (SD 10.1)

0.12

PaO2 (mmHg)

62 (SD 6.6)

69 (SD 17.1)

0.36

PaO2/FIO2

297 (SD 31.3)

327 (SD 82)

0.36

HCO3- (mmol/l)

25 (SD 0.9)

25 (SD 1.5)

0.63

SaO2 (%)

87 (SD 5.3)

88 (SD 7.1)

0.81

tHb (g/l)

121 (SD 5.9)

123 (SD 6.5)

0.52

K+ (meq/l)

3.6 (SD 0.3)

3.8 (SD 0.6)

0.58

Na+ (meq/l)

142 (SD 2.3)

140 (SD 2.5)

0.16

Cl- (meq/l)

107 (SD 2.3)

104 (SD 2.4)

0.04

Glucose (mg/dl)

228 (SD 58)

278 (SD 88)

0.23

Lactate (mmol/l)

1.7 (SD 0.4)

1.9 (SD 0.9)

0.59
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Table 10. Phase II arterial blood gas data on FIO2 0.40.
Elastase

pH

7.39 (SD 0.03)

Saline

p value

7.35 (SD 0.08)

0.24

49 (SD 11.0)

0.14

PaCO2 (mmHg)

43 (SD 3.2)

PaO2 (mmHg)

89 (SD 11)

107 (SD 8)

0.01

224 (SD 28)

268 (SD 20)

0.01

HCO3- (mmol/l)

25 (SD 1.0)

24 (SD 1.0)

0.59

SaO2 (%)

96 (SD 2.8)

98 (SD 2.0)

0.24

tHb (g/l)

126 (SD 4.6)

126 (SD 8.0)

0.93

K+ (meq/l)

3.7 (SD 0.3)

3.7 (SD 0.4)

0.75

Na+ (meq/l)

141 (SD 2.1)

141 (SD 1.9)

0.87

Cl- (meq/l)

105 (SD 2.1)

104 (SD 2.7)

0.44

Glucose (mg/dl)

228 (SD 72)

230 (SD 64)

0.97

Lactate (mmol/l)

1.2 (SD 0.4)

1.6 (SD 0.6)

0.25

PaO2/FIO2
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Oxygen delivery to and consumption by the spinotrapezius muscle
Microvascular PO2

Using phosphorescence quenching microscopy, arteriolar and venular PO2 were measured
in the spinotrapezius (ST) muscle at rest, immediately after a three-minute contraction,
and five minutes after contraction (time 0, 3, and 8, respectively, on the subsequent
graphs) with the animal breathing a FIO2 of 0.21 (Figures 36 and 37) or 0.40 (Figures 38
and 39). With the exception of first post-contraction venular PO2 on FIO2 0.21, and both
the baseline arteriolar and venular PO2 on FIO2 0.21 (p = 0.04, 0.02, and 0.03,
respectively), PO2 was equivalent between groups. In addition, a repeated measures
analysis revealed statistically equivalent arteriolar and venular PO2 across all time points,
for both FIO2 0.21 and 0.40 (p = 0.15 – 0.92).
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Figure 36. Arteriolar PO2 before (time = 0) and after a three-minute contraction
(time = 3 and 8); FIO2 = 0.21.
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Figure 37. Venular PO2 before (time = 0) and after a three-minute contraction (time
= 3 and 8); FIO2 = 0.21.
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Figure 38. Arteriolar PO2 before (time = 0) and after a three-minute contraction
(time = 3 and 8); FIO2 = 0.40.
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Figure 39. Venular PO2 before (time = 0) and after a three-minute contraction (time
= 3 and 8); FIO2 = 0.40.
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Spinotrapezius blood flow

Linear regression of all time matched arteriolar flow ( Q aST ) and venular flow ( Q vST )
measurements (n = 42) revealed a relatively strong correlation (r = 0.68, p < 0.01) (Figure
40). Because arteriolar flow had a greater number of complete data sets compared to
arteriolar flow (n = 54 vs. 43), as well as a lower degree of variability ( x = 25 nl/sec (SD
15.7) vs. 26 nl/sec (SD 18.2), arteriolar flow was used as ST blood flow in hypothesis
testing, and for calculating oxygen consumption.
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Figure 40. Scatterplot and regression line (red) of spinotrapezius arteriolar vs.
venular flow for all matching time points (n = 42), which demonstrates a slope of
0.61 and correlation of 0.68 (p < 0.01) compared to the identity line (green), where
QaST = QvST .
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Tables 11 and 12 report the measured (diameter and blood velocity) and calculated
(blood flow) arteriolar parameters at baseline, and immediately following a three minute
contraction, respectively; there were no differences between experimental groups. Blood
velocity was also unchanged when comparing baseline to post-contraction measures (p =
0.57), thus making increased diameter (p = 0.04) almost solely responsible for the
increase in flow (p = 0.08).
There were no statistical differences in ST arterial (Figure 41) or venular flow (Figure
42) between groups (elastase vs. saline) at any time point (time = 0, 3, and 8 minutes)
while breathing FIO2 0.21 (p = 0.81, 0.20 and 0.92, and p =0.83, 0.37 and 0.68,
respectively). In addition, breathing FIO2 0.40 (Figure 43) did not have an effect on flow,
either between groups at any time point (p = 0.32, 0.48, and 0.63) or when compared to
the same group breathing FIO2 0.21 (p = 0.31, 0.99, and 0.08). However, there was an
increase in ST flow immediately after contraction for both groups breathing FIO2 0.21 and
0.40 (time 0 vs. 3, p = 0.08 and 0.02, respectively), which returned to resting values
within five minutes after the contraction (time 0 vs. time 8, p = 0.27 and 0.22,
respectively).
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Table 11. Primary arteriolar blood flow parameters at baseline.
Elastase

Saline

FIO2 0.21

p value

Blood velocity (mm/sec)

3.4 (SD 1.7)

3.9 (SD 1.9)

0.68

Diameter (µm)

73 (SD 10.5)

84 (SD 28.0)

0.45

Blood velocity (mm/sec)

3.4 (SD 1.7)

3.9 (SD 1.9)

0.68

18.3 (SD 11.1)

25.5 (SD 9.5)

0.32

FIO2 0.40
Blood flow (nl/sec)
Diameter (µm)

67 (SD 14.2)

79 (SD 21.8)

0.32

Blood velocity (mm/sec)

4.3 (SD 2.0)

4.9 (SD 1.3)

0.65

Table 12. Primary arteriolar blood flow parameters immediately post-contraction.
Elastase

Saline

FIO2 0.21
Blood flow (nl/sec)

p value
26.5 (SD 19.7)

49.5 (SD 17.7)

0.20

Diameter (µm)

97 (SD 15.7)

100 (SD 28.2)

0.84

Blood velocity (mm/sec)

3.1 (SD 1.9)

4.1 (SD 1.1)

0.52

28.6 (SD 23.2)

37.8 (SD 9.1)

0.48

FIO2 0.40
Blood flow (nl/sec)
Diameter (µm)

88 (SD 15.0)

91 (SD 12.0)

0.69

Blood velocity (mm/sec)

3.7 (SD 2.2)

5.3 (SD 1.4)

0.25
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Figure 41. Arteriolar blood flow before (time = 0) and after a three-minute
contraction (time = 3 and 8); FIO2 = 0.21.
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Figure 42. Venular blood flow before (time = 0) and after a three minute contraction
(time = 3 and 8); FIO2 = 0.21.
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Figure 43. Arteriolar blood flow before (time = 0) and after a three minute
contraction (time = 3 and 8); FIO2 = 0.40.
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Oxygen consumption

Spinotrapezius oxygen consumption ( VOST ) was calculated from spinotrapezius blood
2

flow and arteriolar-venular oxygen difference (as previously described, page 10) and
converted to µl of O2 per min. VOST was equivalent between elastase and saline animals
2

across all time intervals and conditions (FIO2) (p = 0.18 to 0.86) (Figures 44 and 45).
Although Figures 44 and 45 illustrate a trend towards increased VOST immediately after
2

contraction, a scatterplot of the data (Figure 46) reveals that a single outlier is primarily
responsible for the elevated VOST for the saline group immediately post contraction.
2

When the data were analyzed to determine if there was an increase in VOST with
2

supplemental oxygen, only the final resting measurement on FIO2 0.40 (0.05 µl/min) was
significantly higher than when breathing FIO2 0.21 (0.02 µl/min; p = 0.04 for time = 8,
versus p = 0.28 and 0.36 for time 0 and 3, respectively).
Table 13 and Table 14 demonstrate the contributions of blood flow (convective oxygen
delivery) and oxygen extraction (diffusive oxygen delivery) to VOST . Surprisingly,
2

although not statistically significant, blood flow was greater in the saline group, while
oxygen extraction was higher in the elastase group (Figures 47 and 48).
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Figure 44. Spinotrapezius muscle oxygen consumption before (time = 0) and after a
three-minute contraction (time = 3 and 8); FIO2 = 0.21.
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Figure 45. Spinotrapezius muscle oxygen consumption before (time = 0) and after a
three-minute contraction (time = 3 and 8); FIO2 = 0.40.
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Figure 46. Scatterplot for oxygen consumption (FIO2 = 0.21), indicating a single
outlier at 0.22 µl/min.
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Table 13. Baseline VOST and the respective contributions of blood flow and O2
2

extraction.
Elastase

Saline

FIO2 0.21
VOST (µl/min)

p value
0.035 (SD 0.015)

0.032 (SD 0.024)

0.86

Blood flow (nl/sec)

16.8 (SD 12.6)

18.4 (SD 5.6)

0.82

O2 extraction

0.51 (SD 0.16)

0.29 (SD 0.22)

0.06

0.039 (SD 0.026)

0.070 (SD 0.054)

0.27

Blood flow (nl/sec)

18.3 (SD 11.1)

25.5 (SD 9.5)

0.32

O2 extraction

0.35 (SD 0.21)

0.23 (SD 0.16)

0.29

2

FIO2 0.40
VOST (µl/min)
2

Table 14. Immediate post-contraction VOST and the respective contributions of blood
2

flow and O2 extraction.
Elastase

Saline

FIO2 0.21
VOST (µl/min)

p value
0.034 (SD 0.027)

0.117 (SD 0.106)

0.18

Blood flow (nl/sec)

26.5 (SD 19.7)

49.5 (SD 17.7)

0.20

O2 extraction

0.50 (SD 0.24)

0.29 (SD 0.16)

0.13

0.072 (SD 0.077)

0.100 (SD 0.061)

0.62

Blood flow (nl/sec)

28.6 (SD 23.2)

37.8 (SD 9.1)

0.48

O2 extraction

0.33 (SD 0.30)

0.23 (SD 0.08)

0.45

2

FIO2 0.40
VOST (µl/min)
2
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Figure 47. Oxygen extraction fraction of the spinotrapezius m.; FIO2 = 0.21.
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Figure 48. Oxygen extraction fraction of the spinotrapezius m.; FIO2 = 0.40.
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Muscle performance
Although room air (FIO2 0.21) indices of muscle performance were statistically equivalent
between groups (Table 15 and Figure 49), the saline group had consistently higher peak
force, force-time integral, and fatigue index values. Although there was no statistical
benefit when breathing supplemental oxygen (FIO2 0.40) on either the force-time integral
or fatigue index (p = 0.39 and 0.85, respectively), the force time integral did increase
~18% for both groups.
There was a positive correlation between spinotrapezius muscle oxygen consumption and
“muscle work,” the force-time integral (Figure 50). Although no significant relationship
between fatigue index (FI) and oxygen consumption (Figure 51), there was a trend
toward less fatigue (higher FI) with lower VOST . There was also no relationship between
2

the force-time integral and fatigue index (p = 0.48).
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Table 15. Indices of ST muscle performance (Elastase vs. Saline).
Elastase

Saline

FIO2 0.21

p value

Force-time integral
(N·s/cm2)
Fatigue index (%)

1.33 (SD 0.95)

2.38 (SD 1.21)

0.14

55 (SD 27)

62 (SD 19)

0.66

1.58 (SD 0.74)

2.79 (SD 0.99)

0.05

51 (SD 23)

67 (SD 19)

0.25

0.37 (SD 0.04)

0.43 (SD 0.09)

0.12

59 (SD 3.6)

61 (SD 3.3)

0.24

0.06 (SD 0.009)

0.07 (SD 0.013)

0.29

FIO2 0.40
Force-time integral
(N·s/cm2)
Fatigue index (%)
Mass (g)
Length (L0, mm)
CSA (cm2)
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Figure 49. Spinotrapezius muscle force when stimulated at 80 Hz, and 40 Hz while
breathing FIO2 of either 0.21 or 0.40 (p = 0.47, 0.21, and 0.04, respectively).
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Figure 50. Relationship between oxygen consumption and muscle work, as
measured by the force time integral (FTI) for all available points (p < 0.01; blue
bands represent 95% confidence intervals).
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Figure 51. Relationship between oxygen consumption and fatigue index (p = 0.48;
blue bands represent 95% confidence intervals), where lower fatigue index indicates
more fatigue.

Discussion

Summary, limitations, and review of literature
Overall, the most obvious and concerning issue in the present set of studies is the lack of
a “true” control group. The dependent groups in this study were the elastase and saline
instilled animals. Although one of the primary purposes of these investigations was to
validate an animal model of skeletal muscle dysfunction in COPD, based on the proposed
hypothesis, alterations in muscle structure and function would purportedly be due to
chronic hypoxemia, not necessary attributed to the elastase-induced emphysema. Thus,
at the outset of the project, especially the phase II studies, it was expected that the
elastase-induced emphysema (experimental) group would have significant hypoxemia,
while the saline instilled group (control) would be normoxic; in the end, there was
virtually no difference in PaO2 between groups when breathing room air (62 vs. 69
mmHg, respectively).
In addition to the possibly of a systemic viral respiratory infection, Rat respiratory virus,
in most of my animals, other issues and limitations of this study include a possible
hypotension related decrease in blood flow after administration of the FluoSpheres,
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oxygen consumption values which are lower than predicted, as well as the wide

variability in measures of muscle performance.

Rat respiratory virus
There is little-to-no publicly available information about Rat respiratory virus (RRV);
what little that has been reported comes from the University of Missouri’s Research
Animal Diagnostic Laboratory’s web site (Riley, Simmons et al. 2002) and a platform
presentation from 2002 (Weisbroth 2002), which simply mentions RRV as an “emerging
disease.” Thus, whether the systemic hypoxemia found in my control animals is due to
RRV, or some other infectious agent is not known; however, purportedly serological and
histological data sent to the University of Missouri by VCU’s Division of Animal
Resources from two rats in phase I of this study were indicative of RRV.
RRV has purportedly been identified in research animals world wide. Information from
the University of Missouri (Riley, Simmons et al. 2002) (see web address in
“Bibliography”) indicates that the pulmonary lesions peak at an age of 10-12 weeks, and
by 18 weeks the lungs show signs of resolution. Arterial blood gas data from phase I of
the present study (Figure 26, page 93) seem to be consistent with these observations:
while PaO2 in the elastase group stayed ≤ 80 mmHg for all age groups, PaO2 was low at 14
at 18 weeks old (67 and 84 mmHg, respectively), by 22 weeks of age PaO2 had returned
to normal (~100 mmHg). It appeared that over time, the hypoxemia resolved, possibly
along with the virus and pulmonary lesions. In the meantime, VCU’s Division of Animal
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Resources began housing the animals in an isolated room with filter-top cages for each
animal, in an attempt to prevent air-borne spread of the virus from animal-to-animal.
Thus, phase II in this series of investigations was initiated with the belief that 1) the
filtered cages would minimize the spread and impact of the disease, 2) over time,
systemic arterial PO2 would remain divergent between the elastase and saline groups, as
any infected animals would recover prior to the terminal experiment, and 3) the
hypothesis that chronic hypoxemia effects skeletal muscle oxygen transport and muscle
performance could adequately be tested. Unfortunately the gross necropsy and arterial
blood gas results from phase II not only refute the contention that the animals get better,
but rather it appears that their pulmonary infiltration worsens (sadly there are no
pulmonary necropsy pictures from the phase I set of animals).
For the elastase group, it is impossible to say how much of the hypoxemia was the result
of emphysema as opposed to RRV. However, it appears (Figures 34 and 35, pages 106
and 107) that the lungs of the elastase group have less infiltrate and consolidation than
the saline group. While the PaO2/FIO2 ratio between groups was only slightly different
(297 vs. 327 for the elastase and saline groups, respectively) when breathing room air,
there was a significant difference when breathing supplemental oxygen (224 vs. 268).
Perhaps this is due to more profound ventilation-perfusion mismatching in the
emphysematous animals.
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In addition to pulmonary infiltrates/consolidation, these animals seemed exquisitely
sensitive to anesthesia. Prior to continuous arterial pressure monitoring at the beginning
of the surgery, at least a half-dozen pilot study animals died during the surgery or
experiment while receiving the lowest recommended does of i.v. Saffan (0.294 ml/hr).
The average Saffan dose to maintain a proper plane of anesthesia and a stable systemic
mean arterial pressure (95 to 105 mmHg) was (0.13); a similar sensitivity was also noted
with gas anesthesia (Isoflurane).

MHC isoforms
The proportion of soleus muscle MHC type I increased with age, while type IIa decreased
and type IIb oscillated up and down (Figure 30, page 99). The spinotrapezius muscle
also demonstrated an increased proportion of MHC type I early on, but then a decrease to
baseline by age 30 weeks, while MHC type IIa decreased early and stayed low, MHC
type IIx increased, and type IIb oscillated up and down (Figure 31). Although contrary to
my original hypothesis, which was that the muscle would shift toward less oxidative
fiber-types over time due to chronic hypoxia, it is possible that concomitant muscle fiber
atrophy also occurred, which would result in a decrease oxygen demand. However, there
was no loss of muscle mass over time (Figure 21, page 87), and the muscle mass data
were consistent with those of previous investigators in normal (Delp and Duan 1996) and
chronically hypoxic rats (Deveci, Marshall et al. 2001).
Delp and Daun reported that the spinotrapezius muscle was composed of 41% type I
fibers, 7% type IIa, 17% type IIx, and 35% type IIb (Delp and Duan 1996), which is in
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general agreement with an earlier study that, using slightly different methods, reported
32% white fibers, 32% intermediate fibers, and 36% red fibers (Taylor and Calvey 1977).
These prior data are somewhat consistent with the current results which found MHC
isoforms I, IIa, IIx, and IIb in proportions of 16, 8, 45, and 30%, respectively (Table 7,
page 98). Since the experimental and control animals in the current study were equally
hypoxemic, and there were no differences in MHC isoforms, no definitive conclusions
can be made regarding possible fiber-type transformation. However, it is possible that
the hypoxemia experienced by both groups resulted in a shift towards more glycolytic
fibers (IIa and IIx). In that case, a decrease in type I and increase in type IIx proportions
would be concordant with the proposed hypothesis, and may help explain the discrepancy
between the current and previously published data.
Of interest, and perhaps concern, is the fact that the values for soleus MHC type reported
in Table 7 are drastically different than that of previous investigators in either normal rats
(Delp and Duan 1996) or those exposed to short-term chronic hypoxia (Deveci, Marshall
et al. 2001); these studies report that the soleus is composed of ~80% type I fibers as
opposed the 9% found in the current study. It is possible that either: 1) the severity of
hypoxia in the current group of animals was so severe that their muscles were composed
almost entirely of type II muscle fibers, or 2) the bands thought to represent the various
MHC isoforms on the SDS-PAGE were improperly identified; neither scenario seems
unlikely. Deveci’s animals were breathing a PIO2 of ~85 mmHg, which should give a
PaO2 of ~50 mmHg, at least as hypoxemic as the animals in the current study. In the
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current SDS-PAGE analysis (Figures 28 and 29, page 97), if identification bands were
shifted up (towards a higher molecular weight) three bands, so that the one currently
labeled “IIx” would be MHC I, then the next, and only other significant, band would be
MHC IIb, but there should be virtually no IIb in the soleus (Delp and Duan 1996). A
Western blot, using antibodies specific for MHC I, IIa, and IIb, revealed that this could
be a possibility, especially if one assumes that separation of bands above the “new” type I
was incomplete due to a lower than usual current used for electrophoresis (3.75 mA/gel
as opposed to 15 mA/gel). Of course, if this were the case, then it would also put the
reasonable results of the spinotrapezius muscle into question, as the same scheme was
used to evaluate both muscles.
One study reported finding developmental MHC in the diaphragm of both patients with
severe emphysema and control subjects (Nguyen, Shrager et al. 2000). On a SDS-PAGE
analysis, neonatal/embryonic MHC migrates intermediate to MHC I and MHC IIb, and
could thus be a fifth band that could diminish the proportions of the other bands.
However, this same study found that when normal protein concentrations were injected
into each lane of the gel, there was not enough developmental MHC to produce a band
with SDS-PAGE or to be stained during immunoblotting (Nguyen, Shrager et al. 2000);
thus it is unlikely that there was a fifth band in the region of interest of the current study
to confound the results.
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Tween related hypotension
Despite numerous reports regarding the hypotensive effect of Tween (Marks and Kolmen
1971; Burnell and Maxwell 1974; Maxwell and Rencis 1974; Lorenz, Reimann et al.
1977; Millard, Baig et al. 1977; Eschalier, Lavarenne et al. 1988; Munoz, Karila et al.
1988), it is found in most fluorescent and radiolabeled microspheres which are marketed
for blood flow measurements. In one of the first studies of the hemodynamic effects of
Tween-20, Marks and Kolmen (1971) found an immediate ~70 mmHg drop in mean
arterial pressure in dogs given 5 ml of Tween-20. In addition to hypotension, they also
reported bradycardia and tachypnea, and found pretreatment with antihistamines
prevented these effects. This present study confirms that even minute amounts (0.002%)
of Tween-20 can result in immediate, profound hypotension, but without bradycardia.
Virtually eliminating the Tween, decreasing its percentage to ~5.6·10-5, as described in
Appendix V was a simple and effective way of preventing this anaphylactic-like reaction,
without administering prophylactic antihistaminic agents.

Blood flow
Several studies (Musch and Poole 1996; Poole, Musch et al. 1997; Kano, Padilla et al.
2004) have measured ST blood flow by injecting 15-µm diameter radioactive
microspheres with the animal at rest or during exercise, and then measuring the
radioactivity of the ST after euthanization. Using this method, blood flow to the entire
muscle was measured and made relative to muscle mass, and gave values in the range of
30 to 70 ml/min/100 g (Kano, Padilla et al. 2004).
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Blood flow to the entire muscle was not measured in the current study, and thus flow was
not reported in ml/min/100 g. The results of this study are more comparable to those
which report in vivo resting ST blood flows using the same ST preparation as in the
present study (Lash 1994; Lash 1995; Lash and Bohlen 1995; Smith, Barbee et al. 2004);
these studies report flows in the range of 6-10 nl/sec. These values are approximately
half of what the present study determined. Smith et al’s (2004) blood velocities (3.4 to
4.0 mm/sec) were virtual identical to the present study’s (3.4 to 3.9 mm/sec), but they
were in smaller diameter arterioles (52 µm vs. 79 µm); this would account for the larger
flow values of the current study. Lash had similar size vessels (74 µm), but a different
technique to measure velocity, dual-slit cross-correlation method, may have
underestimated velocity in such large vessels (the method is traditionally used in venules,
small arterioles, and capillaries). Thus, when comparing the current data with these
previous studies, in which PaO2 was normal, chronic hypoxemia does not appear to have a
detrimental effect on ST blood flow.
There are no known studies that have measured both arteriolar and venular flow
concurrently, and thus no empirical data from which to predict this relationship. The
present study measured velocity and diameter of both arterioles and venules at nearly the
same time in order to provide a measure of internal validity for the novel
method/equations developed to measure blood velocity. Figure 40 illustrated the
relationship between arteriolar and venular flow. While the best-fit line (red, slope 0.61)
is close to the identity line (green, slope = 1) (r = 0.68), theoretically one would predict
that they should be the same. Several assumptions went into the derivation of Equations
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17 and 18 (pages 71 and 72): 1) both vessels were perfectly cylindrical, 2) the velocity
profile for both vessels was a Poiseuille parabolic profile (B = 1), and 3) all blood
entering the ST muscle via the arteriole measured also left via the adjacent venule in
which measurements were made.
Each of these assumptions may not be entirely correct. While the arterioles, which have
a greater amount of smooth muscle, are likely cylindrical, the venules, which are more
compliant, may assume a more elliptical cross section, which would affect diameter (d).
This would lead to error in calculating both mean velocity (which uses W/d) and crosssectional area (πd2/4). Although the velocity profile (B) may be different in arterioles
and venules of different sizes (as in the current study), both objective (Pittman and
Ellsworth 1986) and subjective (Schmid-Schoenbein and Zweifach 1975) data suggest
that the profiles are similar in arterioles and venules of similar diameter, of which they
were not in this study. Of most concern is that there were two primary arterioles and
venules in the spinotrapezius preparation used, thus allowing a different route for blood
to enter or leave the muscle than from the measurement site. Due to fewer assumptions
for the arterioles as well as a lower variability in measurements, arteriolar flow was used
for Q ST in all calculations and analyses.

Oxygen consumption
As seen in Table 16, the raw, un-normalized, values for spinotrapezius oxygen
consumption in this study, 0.5 nl/sec, are consistent with those of a previous study from
the same laboratory (Smith 2002). However, Marshall and Davies (1999), reported a
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resting oxygen consumption in the rat hind limb of 0.004 ml/min/g after normalizing for
predicted muscle mass. A nearly 20-fold lower value, 0.00026 ml/min/g, was calculated
for spinotrapezius oxygen consumption when the current data were normalized to onethird of spinotrapezius muscle mass (an approximation of the perfused muscle mass
supplied by the large arteriole from which blood flow and oxygen measurements were
made in this study). Since there were two large arterioles in the field of view using the
current preparation, in addition to the rostral feed artery and any vessels on the ventral
surface of the preparation that are not observed, it is likely that the mass of tissue
perfused in the current setup is much less than the one-third originally predicted (perhaps
as little as one-sixth). Since there is no way to estimate the exact perfused tissue mass,
the current setup does not lend itself to “normalization.” This was also evident when
attempting to normalize the current raw blood flow data to muscle mass (see Table 16).
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Table 16. Resting systemic and tissue (spinotrapezius m.) parameters of oxygen
delivery and consumption from the current study compared to reference values.
Parameter
CaO2 (systemic)

Experimentally

Reference

derived mean values

values

14.6 (SD 1.0)

20

Source for reference values
(Richardson, Leek et al. 2003)

(ml O2/dl of blood)
9.0 (SD 2.9)

CaO2 (tissue)
(ml O2/dl of blood)
CvO2 (tissue)

5.2 (SD 2.7)

(ml O2/dl of blood)
CaO2 – CvO2 (tissue)

3.9 (SD 2.4)

3.5 – 5.0

O2 extraction (tissue)
rest

0.43 (SD 0.21)

0.20

exercise

0.42 (SD 0.23)

0.74 – 0.80

(ml O2/dl of blood)

Blood flow (tissue)

(Nellis, Flaim et al. 1980)
(Nellis, Flaim et al. 1980;
Henderson, Wagner et al. 2002)

1.05E-05 (SD 6E-06)

(dl of blood/min)
Blood flow (tissue)

0.800 (SD 0.50)

30

(Kano, Padilla et al. 2004)

60

(Musch and Poole 1996)

(ml/min/100 g)
Oxygen consumption

0.5 (SD 0.3)

0.05 – 2.0

(Smith 2002)

(nl O2/sec)
Oxygen consumption

3.4·10-5 (SD 1.7·10-5)

(ml O2/min)
Oxygen consumption
(ml O2/min/g of m.)

0.00026 (SD 0.00014)

0.004

(Marshall and Davies 1999)
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Of interest is the fact that while blood flow and oxygen consumption were higher in the
saline group, oxygen extraction was higher in the elastase group (Table 13, page 127).
Although all three of these parameters were statistically equivalent, these differences
were consistent across time (time = 0, 3, and 8 min) and condition (FIO2 0.21 vs. 0.40),
indicating that the difference was more real, and not merely by chance. At rest the higher
blood flow in the saline group was primarily due to larger diameter vessels, as blood
velocity was equivalent (Table 11, page 119). However, immediately after contraction,
the vessel diameters were equivalent, but the blood velocity was higher in the saline
group (Table 12). Thus, the elastase group has both a more pronounced hyperemic
response to exercise as well as having a higher degree of oxygen extraction, but blood
velocity remained constant after exercise. Perhaps the elastase group developed some
degree of right heart failure and cardiac output was impaired compared to the saline
group, and in an effort to compensate, peripheral skeletal muscles became more efficient
at extracting oxygen.
Based on Fick’s principle, mass conservation of oxygen (Equation 22), ST oxygen
consumption ( VOST ) is the product of ST convective oxygen delivery ( Q ST ⋅ CaO ) and
2

2

diffusive oxygen delivery, or oxygen extraction, ( CaO − CvO CaO ).
2

Equation 22
 CaO − CvO
2
2
VOST = Q ST ⋅ CaO ⋅ 
2
2

CaO
2


(

)






2

2
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Although VOST was still lower in the elastase group at all time points, it appears that while
2

its convective oxygen delivery was diminished relative to the saline group, an enhanced
diffusive oxygen delivery helped the elastase group maintain a level of work and oxygen
consumption comparable to that of the saline group (Figure 52, page 148). Based on
Equation 3, enhanced diffusive oxygen transport would be possible if there was either 1)
an increase in area available for diffusion (A), or 2) a decrease in diffusion distance (∆r).
Increased area available for diffusion could occur if there is an increase in capillary
surface area due to increased capillarity of the muscle, while a decreased diffusion
distance could occur if either capillarity truly increased, or if the muscle fibers were
smaller. Unfortunately no histological measures were done on the animals from this
study; however, given that muscle mass and calculated CSA were slightly smaller for the
elastase group (Table 15, page 131), this may partially account for the higher oxygen
extraction.
In a group of patients with COPD and activity matched controls, Richardson et al (2003)
studied oxygen transport during a small-muscle mass exercise, similar to the present
study, in which pulmonary function should not be a limiting factor. For an equal
workload, they did not find a difference in oxygen extraction, nor did they find a
difference in capillarity or aerobic enzyme activity. However, they did find a reduced
capacity for muscular work that was associated with a reduced proportion of type I
muscle fibers and an increase in type II, especially IIx.
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Figure 52. Relationship between ST muscle oxygen consumption and work (FTI).
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Muscle performance
Only two other studies have measured muscle force of the spinotrapezius muscle. Both
Taylor and Calvey (1977), and Suzuki et al (1995) demonstrated that muscle force was
partially fused at 40 Hz and became fully fused by 80 Hz, producing a maximal force of
~0.44 N (45 g); data from the current study concur with these prior results (Figure 53).
However, neither of these studies actually reports the raw force data or standard
deviations from their experiments, but rather the value stated above was calculated from
the representative force tracings in their figures.
The force data from the current study exhibited a large degree of variability (Figure 54);
mean peak force of the spinotrapezius muscle for all data points, when stimulated at 40
Hz, was 51 mN (5.2 g) with a standard deviation of 36 mN (3.7 g); this variability is
much greater than that reported by researchers in eye and tongue muscles (Goldberg,
Wilson et al. 1997; Sutlive, Shall et al. 2000) as well as in the soleus muscle (Segal,
Faulkner et al. 1986). However, when the single outlier is removed from the data set, the
mean force only decreases only 9.8%, to 46 mN, but the standard deviation decreases
25%, to 27 mN. This is still a wide degree of variability. In an attempt to determine if
this was due to the investigators inexperience at the beginning of the study, a scatterplot
was done of all force data over time, Figure 54, which illustrates no learning effect of the
investigator that resulted in less variable and/or increased force values over time. Despite
this variability and no statistically significant differences between groups, the saline
group outperformed the elastase group in every measure of muscle performance (peak
force at 80 and 40 Hz, force-time integral, and fatigue index). As illustrated above,
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Figure 52, VOST was also concomitantly decreased; it would have been interesting to see
2

how these relationships compared at a different work loads (i.e., by increasing
stimulation frequency > 40 Hz, or by increasing the pulse-train frequency > 1 Hz).
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20 Hz

40 Hz

80 Hz

Figure 53. Representative isometric force profile of the spinotrapezius muscle
stimulated at 10, 20, 40, and 80 Hz.
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Figure 54. Scatterplot of force data over time, demonstrating no "learning effect"
by the investigator (r = 0.12).
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Suggestions for future research
Above all else, the viral agent responsible for RRV needs to be characterized, a relatively
non-invasive way in which to test animals for RRV needs to be developed, and an
effective systematic and comprehensive prevention and control procedure needs to be
developed.
Due to the unknown effects of prolonged anesthesia as well as the variability in muscle
force measures, it would be useful to know the intra-animal reliability of repeated
measures of the course of an experiment under the same conditions in normal animals. In
addition, it would be useful to determine intra-animal reliability of repeated measures of
blood velocity and blood flow under both steady state and exercise conditions.
The stimulation protocol used did not result in a significant increase in VOST immediately
2

after contraction. A graded exercise protocol could help determine the relationship
between ST VOST and muscle work as well as possibly define VOST
2

2 max

, so that future

investigators would know more specifically what workload a given stimulation protocol
would result in.
As noted above, characterization of the spinotrapezius muscle histochemically with
regard to muscle-fiber types, fiber cross-sectional area, and capillarity would provide
useful information in interpreting the findings from the present study
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Conclusions
Due to a presumed Rat respiratory virus, which likely resulted in the control group
(saline) being nearly as hypoxemic as the experimental group (elastase-induced
emphysema), as well as a wide degree of variability in several independent measures, the
present study was not able to definitively test the proposed hypothesis that chronic
hypoxemia (due to emphysema) leads to both a diminished oxygen supply and demand in
skeletal muscle.
Compared to previous studies, animals with elastase induced emphysema also appeared
to have a dramatic transformation of muscle fiber types away from oxidative and toward
more glycolytic, especially type IIb. However, these proportions were virtually the same
as that seen in the control group which was normoxic 12 weeks after instillation, and
increasing age actually lead to an small increase in MHC I (as seen in normal aging).
Although many of the results of the present study were not statistically significant, they
were consistent over time and are likely of physiological significance. All measures of
muscle performance were lower in the elastase group. In addition, spinotrapezius oxygen
consumption and blood flow were lower in the elastase group. Only oxygen extraction
was higher in the elastase group, likely due to diminished fiber cross-sectional area. The
addition of supplemental oxygen during isolated, small-muscle mass exercise did
improve the force-time integral ~18% in both groups, suggesting that muscle work in
these hypoxemic animals may be limited by oxygen supply.
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Thus, the data on muscle fiber type, oxygen consumption and muscle performance
suggests that elastase-induced emphysema in rats does lead to a similar skeletal muscle
dysfunction that is seen in humans with COPD, and indicates that it is a valid animal
model of skeletal muscle dysfunction in COPD.
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Appendix I.
Thermostatic animal platform
A thermostatic animal platform for intravital microscopy (Figures 55 and 56) was
modified from one originally designed, built, and described by Aleksander S. Golub
(Golub and Pittman 2003). The current device was specifically designed for the
spinotrapezius muscle, and incorporates a force transducer and tension adjuster for
contractile measurement in skeletal muscle. This device allows both transmission and
episcopic illumination of thin tissues while maintaining both the animal and tissue at a
physiologic temperature. In addition, it allows muscle contractile measures to be made
while the muscle is at its physiologic length and temperature; this is important, because
muscle blood flow, contractile performance and metabolism decrease in response to subphysiologic temperatures. A disclosure was made with the VCU Office of Technology
Transfer, the device was assigned to the VCU-Intellectual Property Foundation, and it has
been protected and is currently being marketed to potential licensees. The following are
the photographs, bill of materials, and detailed drawings of the device.
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Figure 55. Thermostatic animal platform with force transducer and tension
adjuster.
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Figure 56. Rat on thermostatic animal platform with spinotrapezius muscle
connected to force transducer.
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Bill of materials
I. Platform (Figure 57)
A. Polymer Plastics Corp., http://www.polymerplastics.com/transparents_lexan.shtml
1. Clear Lexan sheets
a. Base (Figure 58)
i. 11 x 9 x .250” (280 x 230 x 6mm) +/-0.010-0.029

$28.17

b. Upright (Figure 59)
i. 11 x 1.97 x .250” (280 x 50 x 6mm) +/-0.010-0.029

$18.66

c. Window box (Figure 60)
i. 1.260 x 10” (32 x 254.0mm), 0.093 +/-0.010-0.029

$17.85

ii. 1.260 x 3” (32 x 76.2mm), 0.060 +/-0.010-0.029

$17.17

iii. 1.220 x 8” (31 x 203.2mm), 0.030, +/-0.010-0.029

$27.28

II. Animal heating tray
A. VCU Custom Design and Fabrication
1. L-shaped 1 mm thick aluminum, 80 x 250mm/30 x 250mm

$15.00

II. Animal heater:
A. Minco Products, Inc., http://www.minco.com
1. Standard Kapton heater
a. 3 x 9”, 14.2Ω, 12” lead, PSA backing, no UL marking
b. Part # HK5472R14.2L12B

$129.10

2. Heaterstat controller for standard Kapton heater# 1 above
a. Part # CT698-1005T39CL1
3. Neoprene foam insulation for #1 above
a. Part # IN5176N1B(-)
4. Window heater:

$5.00
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a. Standard Thermal Clear Heater
b. 0.9 x 2”, 43.3Ω, PSA backing, 12” lead
c. Part # H6702R43.3L12B

$117.75

5. Heaterstat controller for window heater
a. Part # CT698-1010T37CL1
III. Optical window:
A. Edmund Scientific, http://www.edmundoptics.com
1. Window Glass 25 x 63.5 x1mm AR CTD
a. Stock # NT32-739, Part # 32739

$14.90

IV. Power supply
A. Elpac Power Systems, http://www.elpac.com
1. Power supply
a. 100-120V AC input, 15.0V, 1.20A, 18W max output
b. Part # WM1815/1.2-76

$42.09

V. Other
A. Miscellaneous size screws, thumb nuts, DC power connector, plastic box to
contain electronics, 5 x 5mm acrylic rod, spring for width adjuster, E6000
Industrial Strength Adhesive ((clear) Eclectic Products, Inc.), and foam for
pedestal insulation
Total cost

≈ $30.00
≈ $460.00
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Appendix II.
Distress scoring sheet
Table 17. Distress scoring sheet. Adapted from Lloyd and Wolfensohn’s work
(1999), validating this distress scoring system with respiratory parameters with the
elastase-induced emphysema model in the rat.
Parameter
Appearance

Descriptive characteristic
Normal
General lack of grooming
Piloerection, fresh ocular and nasal discharges
Piloerection, hunched up
Above and eyes half closed

Score
0
1
2
3
4

Natural behavior

Normal
Minor changes
Less mobile and isolated, but alert
Restless or very still, not alert

0
1
2
3

Hydration status

Normal
Abnormal skin pinch test

0
5

Clinical signs

Normal Respiratory rate and pattern
Slight changes, increased rate only
Increased rate with abdominal breathing
Decreased rate with abdominal breathing
Marked abdominal breathing and cyanosis

0
1
2
3
4

Provoked behavior

Normal
Minor depression or exaggerated response
Moderate change in expected behavior
Very weak and precomatose

0
1
2
3

Total

0-19

Animals scoring ≥ 12/19 will be euthanized
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Appendix III.
Preparation of Albumin-bound Pd-porphyrin phosphorescence
probe
General precautions
Use proper personal protective equipment and procedures: 1) respirator, when using
powdered chemicals, 2) safety glasses, 3) gloves, and 4) wash any skin thoroughly if
contaminated.

Solubilization of Pd-porphyrin
Table 18. Ingredients for 20 ml phosphorescence probe (10 mg/ml)
Item
Tris base
BSA
Pd-MTCPP
DMSO
Deionized H2O

Quantity

1g
1.32 g
200 mg
4-5 ml
100 ml, divided

Table 19. Solubilization – equipment and supplies
Scale
pH meter
Stirrer & micro stirring bar
Spatula & small weigh boats

10 ml beaker
30 ml beaker
25 ml graduated cylinder
Glass pipette & bulb

Mortar & pestle
Mug (“don’t”)
Parafilm
Aluminum foil

1. Prepare 2.75 M Tris base solution:
a. Dissolve Tris into 3 ml of deionized H2O in 10 ml beaker.
b. Cover with parafilm.

189

190

2. Prepare 1 mM BSA solution:
a. Poor 20 ml of deionized H2O into a 30 ml beaker with micro-stir bar.
b. With beaker on stirrer, use spatula to slowly add small portions of BSA
(just sprinkle enough to cover the surface, letting each application
dissolve). This takes at least 60 minutes.
c. Use pipette to add a few drops of Tris base as needed to keep pH between
7.3 and 7.7.
d. Color should gradually turn a clear yellow by the completion of this step.
3. In meantime, gently crush granules of Pd-MTCPP into mortar with pestle until
you have a fine powder (wear respirator).
4. Slowly add small portions of Pd-MTCPP to BSA solution on the stirrer (just
sprinkle enough to cover the surface, letting each application dissolve).
a. This will take ~30 minutes.
b. Protect solution from light, wrap beaker with aluminum foil.
c. Rinse excess Pd-MTCPP from mortar and pestle with few drops of
DMSO, and poor into beaker; rinse a second time.

d. Maintain pH between 7.3 and 7.7 with drops of Tris base.
e. Cover with “don’t” mug and leave Pd-porphyrin solution on stirrer
overnight.
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Dialysis of Pd-porphyrin
Table 20. Ingredients for 1 L of dialysis solution
Item
PBS
PVP
Deionized H2O

Quantity
1 packet
55 g
1L

Table 21. Dialysis – equipment and supplies
Large weigh boats
Large stir bar
1 L beaker
600 ml beaker
Two 100 ml beakers with deionized H2O

10 ml beaker
3 Spectra/Por® 4 membranes, 10 cm long
Spectra/Por® clamps (3 white, 3 orange)
Plastic forceps & small needle
Large glass syringe with Teflon needle

1. Prepare 1 mM dialysis solution:
a. Dissolve PBS into 1 L of deionized H2O.
b. Fill 10 ml beaker with PBS (for volume restoration)
c. Heat remaining PBS buffer solution to approximately 50° C on stirrer.
d. Slowly add PVP to PBS buffer solution (wear respirator). It takes ~60
minutes to dissolve completely.
2. Poor 500 ml of dialysis solution into 600 ml beaker, and cover remaining beaker
with parafilm.
3. Prepare dialysis bags:
a. Place one Spectra/Por® 4 membrane into 100 ml beaker with deionized
H2O, let sit for 5 minutes.
b. In meantime, withdraw Pd-porphyrin solution into syringe.
c. Clamp one end of membrane with white/weighted clamp.
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d. Open other end gently with small needle, and inject ~8 ml of Pd-porphyrin
solution using glass syringe with Teflon needle.
e. Place orange clamp on other end of membrane, while leaving some air at
top.
f. Rinse in a separate 100 ml beaker with deionized H2O.
g. Place “bag” into dialysis solution.
h. Repeat for 2nd and 3rd membrane
4. Cover beaker on stirrer with aluminum foil, and let dialyze overnight (18 to 20
hours).
5. Remove bags from beaker and replace “old” dialysis solution with remaining
dialysis solution.
6. Leave solution on stirrer for 4 – 6 hours, or longer.
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Final processing
Table 22. Final processing – equipment and supplies
100 ml beaker with deionized H2O
Two 50 ml beakers
25 ml graduated cylinder
115-ml sterilization filter unit
< 10 ml PBS (from “Dialysis,” step 1b)

Vacuum pump
50 – 0.5 ml microcentrifuge tubes with cap
Pipette and sterile pipette tip
Dewar and 4” liquid N2

1. Remove dialysis bags from solution, rinse in 100 ml beaker with deionized H2O,
and dry with Kimwipe.
2. Unclamp dialysis bag and pour contents into 50 ml beaker, and squeeze remaining
solution out.
3. Measure volume of solution in graduated cylinder.
4. Using vacuum pump, filter solution through sterilization filter unit, and return to a
clean 50 ml beaker.
5. Rinse the graduated cylinder, original beaker, and filter unit with enough PBS to
increase to volume measured in step 3 to 20 ml.
6. Pipette out 0.5 ml of solution into microcentrifuge tubes and close cap tightly.
7. Drop into liquid N2 filled dewar.
8. Store in -80° C freezer, room 3-012.
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Usage
Table 23. Usage – equipment and supplies
20-G needle, 22 mm long with blunt tip
1 ml empty syringe with Luer-Lok tip
One 0.5 ml microcentrifuge tube of probe
1 ml syringe filled with PBS

1. Remove a 0.5 ml microcentrifuge tube of Pd-porphyrin phosphorescence probe
from freezer and thaw at room temperature.
2. Using 20-G needle and syringe, slowly withdraw solution from microcentrifuge
tube (avoid bring any air bubbles into solution).
3. Inject into animal via stopcock and catheter
4. Flush “probe” syringe with 0.5 ml PBS, then inject into animal.
5. Flush catheter with 0.3 to 0.4 ml PBS.
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Bill of materials
Table 24. Pd-porphyrin – bill of materials for 20 ml of probe
Item
Oxyphor R0
(Pd-meso-tetra
(4-carboxylphenyl)
porphyrin)

Product Common
Supplier
number abbreviation
Pd-MTCPP
Oxygen Enterprises, Ltd.,
Philadelphia, PA

MW Quantity
896

200 mg

Trizma ® base
(CH2OH)3CNH2

T-1503

Tris

Sigma-Aldrich, Inc.,
St. Louis, MO

121.14 1 g

Dimethyl sulfoxide
(CH3)2SO

D-8779

DMSO

Sigma-Aldrich, Inc.,
St. Louis, MO

78.13

Albumin bovine
serum,
Fraction V

A-9647

BSA

Sigma-Aldrich, Inc.,
St. Louis, MO

66,000 1.32 g

Polyvinylpyrrolidone

856568

PVP

Sigma-Aldrich, Inc.,
St. Louis, MO

55,000 55 g

Phosphate buffered
saline (0.01 M), pH
7.4

P-3813

PBS

Sigma-Aldrich, Inc.,
St. Louis, MO

1 packet

Spectra/Por ® 4
dialysis membrane

132700

Spectrum Laboratories, Inc.,
Rancho Dominquez, CA

3, 10 cm
long

Spectra/Por ® closures 132751

Spectrum Laboratories, Inc.,
Rancho Dominquez, CA

3 white/
3 orange

NALGENE Co.,
Rochester, NY

1

115-ml sterilization
filter unit

121-0020

4-5 ml

Appendix IV.
Molecular biology solutions and mixtures
Agents used in the electrophoresis procedures were electrophoretic grade (Bio-Rad).

MHC extraction solution
The MHC extraction solution (pH 6.5) had a final composition of 0.3 M NaCl, 0.15 M
Na2HPO4 and 10 mM EDTA, and was stored at 4° C.

SDS-polyacrylamide gels
The 8% separating gel was composed of the following stock solutions: 68.16% glycerol,
29% acrylamide-bis (2%C), 1.5 M Tris (pH 8.8), 1 M glycine, 10% SDS, which were
degassed for 15 minutes prior to initiation of polymerization with 10% ammonium
persulfate (made fresh) and N,N,N’,N’-tetramethylethylenediamine (TEMED).
The 4% stacking gel was composed of the following stock solutions: 68.16% glycerol,
29% acrylamide-bis (2%C), 0.5 M Tris (pH 6.8), 100 mM EDTA, 10% SDS, as well as
deionized water, which were degassed for 15 minutes prior to initiation of polymerization
with 10% ammonium persulfate (made fresh) and TEMED.
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Buffer solutions
The sample buffer (2x Laemli) was composed of the following solutions: 0.5 Tris-HCl
base, 10% SDS, 68.16% glycerol, 2 β-mercaptoethanol, and 0.05% bromophenol blue
dye.
The upper running buffer had a final composition of 100 mM Tris base, 150 mM glycine,
and 0.1% SDS in deionized water; the lower running buffer was half as concentrated as
the upper. Both solutions were made immediately before gel electrophoresis and were
stored at 4° C.

Staining procedure solutions
The fixative enhancer solution had a final composition of 50% methanol, 10% acetic
acid, 10% fixative enhancer concentrate (Bio-Rad), and 30% deionized, distilled water.
The staining solution was made with 1) silver complex solution, 2) reduction moderator
solution, 3) image development reagent, and 4) development accelerator solution (Silver
Stain Plus, Bio-Rad).

Appendix V.
Preparation of FluoSpheres
Dilution of FluoSpheres
The 2.0 µm diameter FluoSpheres (F-8823, Carboxylate-Modified Microspheres,
Molecular Probes, Inc., Eugen OR) had an original concentration of 4.5·109 particles/ml
in an aqueous suspension with 0.02% Tween-20 and 2 mM sodium azide. The goal
concentration for injection was 4.5·108 particles/ml. In addition to a 10-fold dilution, due
to the histaminergic properties of Tween, the particles were “washed” as described below
to yield 3-ml of solution (enough for 2-3 experiments). This is best done immediately
prior to an experiment, no more than 48 hours before.
1. With the lid on tight, place the vial of FluoSpheres in an ultrasonic water bath for
five minutes.
2. Put micro-stir bar in vial, place vial on stirrer for at least five minutes (cover to
protect from light).
3. Pipette 0.3 ml of the probe into a small translucent plastic bottle and then add 2.7
ml of normal saline.
4. Centrifuge for 20 minutes at 3,600 rpm (~1,000 g).
5. Withdraw 2.5 ml of supernatant and replace it with normal saline.
6. Centrifuge again for 20 minutes at 3,600 rpm (~1,000 g).
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7. Withdraw 2.5 ml of supernatant and replace it with normal saline.
8. Place back on stirrer or in vortex mixer to re-suspend the particles
This should reduce the Tween-20 concentration to ~5.6·10-5%, while maintaining a
particle concentration of ~4.5·108 per ml.

200

Usage
Prior to use in an experiment:
1. Place the vial of diluted solution in the ultrasonic bath for five minutes.
2. Use vortex mixer to re-suspend particles
3. Withdraw 0.6 to 1.0 ml of solution into a 1-ml syringe, and cap (leaving some
room for air).
4. Immediately prior to injecting into the animal, briefly place the syringe in the
vortex mixer.
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